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Abstract 
This thesis is based on research on the epidemiology and prevention of HIV among 
adults in rural Masaka district, Uganda (1989-2010). Arising from this research are 10 
published papers, which I have used to explore three research questions: (i) what are the 
trends in HIV prevalence and incidence in rural Uganda? (ii) what are the key 
determinants of these trends? (iii) what new strategies could be used to prevent HIV 
infection in this population? 
The studies involved four adult cohorts: a general population cohort to monitor HIV 
prevalence and incidence trends through annual household and serological surveys; an 
STDlbehavioural intervention cohort; a cohort for HIV vaccine preparedness studies; 
and a cohort of HIV-negative women in discordant couple relationships to evaluate HIV 
biomedical interventions. 
The findings from the published papers are summarised. Additional analyses were 
conducted to include prevalence and incidence data up to 2008. The time trends were 
examined using a proximate-determinants framework. A comparison of the observed 
trends was also made with other available national data as well as data from two other 
African countries. 
There was a significant decline in HIV prevalence for all ages in the 1990s followed by 
an increase in the 2000s. Similarly, HIV incidence declined significantly in the 1990s in 
all adults although there were no clear trends in the 2000s. A net outflow of HIV 
positive migrants, mortality among HIV positive individuals and a decrease in risky 
sexual behaviour in the 1990s seem to have been important factors in explaining the 
decline. The increase in prevalence in the 2000s is explained partly by improved 
survival due to ART and possibly complacency leading to increased risky sexual 
behaviour. 
Two HIV intervention trials (of STDlbehaviour change and a phase 3 vaginal 
microbicide) are also discussed. Neither trial showed any effect on HIV transmission. 
To explain the findings from these trials, a conceptual framework for discussing 
negative results from HIV prevention trials has been used .. The possible explanation for 
the negative results was that the concepts were right but the actual interventions were 
"inert" or insufficient to demonstrate impact. There was also evidence that there were 
deficiencies in the design and delivery of the school-based component of the 
behavioural intervention. In recognition that the epidemic continues unabated, I have 
addressed priorities for future HIV prevention research on biomedical and behavioural 
interventions. 
The cohorts established and research capacity built will continue to provide new 
opportunities for monitoring and preventing the transmission of HIV in this population. 
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Chapter 1. Introduction 
Summary 
This chapter provides a background to the epidemiology of HIV in Uganda, based on 
research conducted in cohorts of the rural adult population in SW Uganda. In this 
chapter, I describe the overall research programme, its development, and main findings 
from this research on: (i) trends in, and risk factors for HIV infection; (ii) the impact on 
HIV incidence in a sexually transmitted disease (STD)/behavioural interventions trial 
and (iii) the impact on HIV incidence in a phase III vaginal microbicide efficacy trial. I 
describe the key determinants of HIV incidence and prevalence using a proximate-
determinants framework, and also explain which of these have been addressed by the 
various studies in this thesis. I played a key role in setting up and developing these 
studies, directing the epidemiological research and implementing the trials. I also 
present the objectives of this thesis and the papers that were published in peer-reviewed 
journals between 2000 and 20 I O. 
1.1 Background 
After more than two decades, the global spread of HIV continues, with approximately 
2.6 million new infections in 2009(1). Over 90% of new infections occur in low income 
countries, with the majority occurring in sub-Saharan Africa (SSA). In SSA an estimated 
1.8 million people became infected in 2009. HIV has had a large impact on economic 
growth and the health sector in heavily affected countries(2-4). However significant 
scientific knowledge has been gained to date that has helped us understand the 
determinants of HIV transmission, trends in HIV infection, the socio-demographic 
impact, and virological and immunological characteristics of the virus. 
Though the spread of HIV infection in SSA has been shown to occur predominantly 
through heterosexual transmission, African studies reveal substantial between-country and 
within-country heterogeneity in HIV prevalence and incidence rates(5-7), and the 
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occurrence of a wide variety of HIV sub-types. The most predominant HIV -1 subtypes in 
Africa are A, C and D, of which subtypes A and D account for most (over 95%) of the 
infections in Uganda(8). The HIV subtype in East and South Africa is type-l and the use 
of the term HIV in this thesis thereafter I refer to HIV-1. 
From the late 1980s, several systems were set up in Uganda to monitor the HIV 
epidemic. These included the establishment of population-based epidemiological studies 
to determine HIV risk factors, the prevalence and incidence of infection, 
epidemiological trends, as well as the impact on mortality and fertility(9-1 0). In addition 
to these studies, the HIV epidemic has been monitored through a Ministry of Health 
sentinel surveillance system using antenatal and STD clinic attendees, and through 
periodic national sero-behavioural surveys. Both the epidemiological surveys and the 
national surveys have provided valuable data for monitoring trends as well as for 
planning and policy formulation in Uganda. 
There has been some success in controlling the HIV epidemic in some countries in SSA, 
including Uganda which was one of the first African countries to report HIV infection in 
the early 1980s(11-13). The success of HIV control in Uganda, as evidenced by a fall in 
prevalence and incidence rates throughout the 1990s, has been attributed to a range of 
public health interventions including the establishment of the National AIDS Control 
Programme by the Ministry of Health, which implemented wide-scale health education 
(based on the "Abstinence, Be faithful, and Condom use (ABC)" strategy), HIV 
voluntary counselling and testing (VCT), and treatment of STDs(11). Despite these 
interventions HIV prevalence and incidence rates remain high and the decline in HIV 
prevalence observed in the mid and late 1990s has stopped. There is recent evidence 
indicating a levelling otT of infection rates, and a possible increase in certain age 
groups( 14). 
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1.2. The Mission of Medical Research CouncillUganda Virus 
Research Institute (MRC/UVRI) Research Unit on AIDS 
The MRCIUVRI Unit was established in 1989 in response to the rapidly expanding 
epidemic of HIV/AIDS in Uganda. The mission of the Unit is: (i) to investigate and 
document the determinants of HIV transmission and subsequent disease progression in an 
African context, (ii) to develop and evaluate effective interventions and (iii) to formulate 
new strategies for preventing HIV transmission and alleviating its medical and social 
consequences. The research findings are intended to inform health policy in Uganda and 
elsewhere, and contribute to the translation of research into policy and practice both 
locally and internationally. 
1.3. Objective of this thesis 
The overall objective of this thesis is to describe and critically examine research on the 
epidemiology and control of HI V infection in rural Masaka district, South-West Uganda 
from 1989 to 2010. The thesis explores three related research questions which have 
implications for the prevention of HI V transmission in African populations, based on the 
mission of the MRCIUVRI described above. 
i. What are the trends in the epidemiology of HIV in Uganda? 
II. What are the key determinants of these trends? 
iii. What new strategies could be used to prevent HIV infection in this population? 
The research I will examine is based on work I conducted using rural population-based 
cohorts in Masaka district and comprises 10 papers published in peer-reviewed journals 
between 1999 and 2010. 
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1.4. The papers submitted as part of this thesis 
Paper I. 
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Paper 8. 
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infection (Microbicides Development Programme 301): a phase 3, 
randomised, double-blind, parallel-group trial. Lancet 2010; 376: 1329-
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1.5. Thesis outline 
The Introduction (chapter 1) describes the overall research programme, its development, 
a summary of the results from the published papers and the key role I played in the 
research. Chapter 2 critically examines the trends in HIV incidence and prevalence 
observed during the study period. Chapter 3 describes the interventions implemented to 
prevent HIV transmission in these cohorts and examines why some interventions have 
shown no impact on HIV transmission. Chapter 4 looks at gaps in our knowledge of 
HIV epidemiology in Uganda and suggests priority areas for future HIV research and 
interventions. Finally chapter 5 synthesises the answers to the research questions in the 
thesis based on my critical review of the research. 
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1.6. MRCIUVRI Uganda rural population based cohorts and 
studies 
1.6.1. Study area and population 
Uganda, a land-locked country located close to the equator in East Africa, is one of the 
countries that have experienced the most severe effects of the HIV epidemic. The 
country was initially regarded as the "epi-centre" of the HIV epidemiq in Africa. HIV 
was first reported in 1983 on the shores of Lake Victoria in Rakai district spreading 
initially to the neighbouring district of Masaka and the rest of the country by 1986( IS}. 
It was partly because of this epidemiological background as well as local political 
support and the accessibility of the study area that Masaka district was chosen by the 
MRCIUVRI for the rural-based HIV epidemiological research and subsequent HIV 
intervention studies. 
The study population where all the different studies were conducted comprised residents 
of Masaka rural district. The population was fairly stable with relatively low in- and out-
migration. The district is located about 37 kms away from the Equator with an average 
altitude of 115m above sea level and the district capital (Masaka town) is about 120 km 
from Kampala. There are several ethnic groups, with the Baganda people 
predominating. The main language spoken is Luganda. The major economic activity in 
the district is agriculture with food crops (bananas, pineapples, and tomatoes), cash 
crops (coffee), cattle ranching, and fishing on Lake Victoria. There are industries that 
include coffee processing, soft drinks factories, and metal works. 
The population of Masaka district is predominantly rural with a total of 831 ,300 people 
including 420,000 females and 411,300 males. They reside in scattered households with 
an average household size of approximately 6 persons. Of all residents approximately 
50% are female and 56% are aged 13 years and below. Overall the population is 
predominantly Christian, with Roman Catholics and Protestants accounting for 
approximately 65% and 10% respectively. Only about 25% are Moslems. The 
proportions may vary slightly from one community to another. 
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Masaka di strict (Figure 1.1) was one of the first districts in Uganda to be hit by the 
HIY/AIDS epidemic and as a result many NGOs, both loca l and international, started 
work in the area fro m the late 1980's. 
Figure 1.1 Map of Uganda showing Masaka district 
1.6.2. Populatiol1 cohorts al1d study designs 
This thes is is based on data from a number of population based cohorts in Masaka 
district (Figure 1.2). I was instrumental in setting up and leading these cohorts (as 
described in section 1.8). Summarised in the fo llowing sections are the population 
cohorts in which the various studies were conducted. All cohorts were se lected from 
rural populations in different parts of Masaka di strict and with no substantial di fferences 
in their characteristics. 
20 
Figure 1.2 Map of Masaka district showing location study cohorts 
MAP OF MASAKA DISTRICT SHOWING THE LOCATION OF 
STUDY AREAS 
KEY 
ｾ＠ STDI1 EC TRIAL PARISHES 
ｾ＠ CENERAL POPULATION COHORT 
L:j HIV NECATIVE COHORT 
ｾ＠ TRANS AfRICAN HICHWAY 
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1.6.3. General population cohort 
The first cohort is a general population cohort, initially of approximately 10,000 people 
residing in 15 neighbouring villages established in 1989. The study area of the general 
population cohort is a rural sub-county situated about 32 km from Masaka town and 16 
km from the international trans-African highway. At the lIth annual survey (1999) we 
aimed to increase accrual of HIV events in order to allow more reliable estimates of 
HIV incidence and prevalence and also to yield additional cases to be recruited into the 
former natural history cohort (now known as the rural clinical cohort). The cohort was 
thus expanded to cover an additional ten villages with a population of approximately 
8,000. For logistical convenience, the new villages were adjacent to the old villages 
(figure 1.3) to the south and south east and in the same administrative unit (sub county). 
Seasonal dirt roads and footpaths connect all the villages. The characteristics of the new 
villages were generally similar to ｴｨｾｳ･＠ of the old villages. One difference was that the 
new villages included the main trading centre of the sub county. A comparison of 
demographic characteristics between the sets of villages indicated that the residents 
from the new villages were more likely to have attained secondary or higher education, 
and to be separated or widowed, than those of old villages. Despite the fact that the old 
villages had been surveyed for 10 years and received HIV health education repeatedly, 
the HIV prevalence at the lIth annual survey was 6.1 % overall, 5.7% in the new 
villages and 6.4% in the original villages (p-value=0.25)( 16). 
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Figure 1.3 Map showing location of old and new study villages of the 
general population cohort 
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Data from the general population cohort are included in papers 1-5 (12, 14, 17- 19) . Of 
these, only in paper 4 are data presented including both old and new villages. The 
overall aim of establishing thi s cohort was to document the course of the HIV epidemic 
and its biologica l and behavioural determinants in rural Uganda. The cohort has been 
under annual surveillance since late 1989. This includes annual mapping of the 
households in each village followed by collection of soc io-demographic data (res idence, 
migration and vital status of all res idents)(20). A medical and serologica l survey fo llows 
the soc io-demographic survey which includes administering an individual medica l 
questionnaire, a brief phys ica l examination and collecti on of a blood sample from all 
consenting individuals aged 13 years and above. HIV counse lling and testing is offered 
to all those who prov ide a blood sample(9). The annual surveys are preceded by 
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community consultations and mobilization to explain the different aspects of the 
research and to seek community consent. 
The cohort has provided valuable data for understanding the epidemiology of HIV in 
rural Uganda. These include estimates of baseline HIV prevalence by age and sex, and 
trends in annual incidence and prevalence, HIV-associated morbidity and mortality, HIV 
risk factors, and the socio-demographic impact of HIV. This knowledge subsequently 
led to setting up intervention cohorts in the district and designing studies to evaluate 
new strategies for the prevention of HIV infection. 
1.6.4. STIlbeltavioural intervention cohort 
The second cohort (STD intervention cohort), in the same district but geographically 
separated from the general population cohort described above, was established in 1994 
to evaluate the impact of improved management of STDs on HlV transmission, with or 
without behavioural change interventions (Papers 6-8)(21-23) in 18 rural communities 
(approximately 96,000 adults). The trial aimed to determine the efficacy of Information, 
Education and Communication (lEC) alone and in combination with improved Sexually 
Transmitted Diseases (STD) management in reducing HIV transmission. Each 
community was a parish, a small administrative division of a district, with an average 
population of about 8,500 people. The study communities were about one hour apart by 
car which reduced the risk of contamination of interventions. This trial consisted of 
three arms with six communities in each arm. In arm A, a standardised behavioural 
intervention alone was implemented (community and school based). In arm B the same 
behavioural intervention as in arm A was implemented and in addition improved STD 
management was implemented through government and private health units. The STD 
component consisted of training health workers in all health facilities in syndromic 
management, counselling on risk reduction, partner notification, health education, 
regular supervision, and regular provision of essential supplies and drugs necessary for 
effective STD management. 
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The remaining 6 communities comprised the comparison arm C and received routine 
government health services, general community development activities related to 
income generating activities, and home-based care for elderly and bed ridden patients. In 
addition in arm C, health promotion seminars were conducted in each community on 
selected health topics (malaria, breast feeding, family planning and diarrhoeal diseases). 
The impact of the interventions was assessed through three Knowledge, Attitude, 
Behaviour, Practice (KABP) and serological surveys conducted at 18-24 months 
intervals in a sample of 750-1000 adults (13+ years) in each community. The sample 
was obtained by surveying 3-5 villages closest to the health unit. 
1.6.5. High HIVprevalence cohort 
Between 2002-2004, a third cohort of 1000 HIV negative adults from three rural high 
HIV prevalence communities (Figure 1.2) was established for conducting feasibility 
studies for HIV prevention trials including vaccine preparedness studies (Paper 9)(24). 
The study was conducted in three neighbouring rural communities in Masaka district, 
Uganda. The communities were selected to participate based on experience of HIV 
prevention research, previously high HIV prevalence, and presence of a health facility 
from which some study activities could be conducted. The HIV vaccine preparedness 
work comprised epidemiological studies to estimate baseline prevalence, incidence and 
predictors of HIV infection and studies to assess willingness to participate in preventive 
HIV vaccine trials (Paper 9)(24). First, a census of all residents in the three communities 
was conducted. Using the census lists, individuals were then contacted in person and 
invited to participate in the house-to-house survey. The survey was conducted one 
community at a time, until a sufficient sample size had been achieved. Individuals were 
enrolled if they were aged 18-60 years, HIV negative, clinically healthy and willing to 
give written informed consent, be tested for pregnancy (females), undergo sexual 
behaviour risk assessment, be counselled and tested for HIV and receive test results. 
At enrolment, study information was given, written informed consent obtained and an 
interviewer administered questionnaire used to collect information on demographics, 
vaccine knowledge, sexual risk behaviours and medical history. Blood was drawn for 
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HIV serology. Female participants were asked to provide a urine sample for pregnancy 
testing. 
HIV incidence in this cohort was shown to be similar to that in the general population 
cohort and the STO intervention cohort (approximately 1-2%) and was thus considered 
not high enough for designing future intervention trials whose end point is often HIV 
incidence. 
1.6.6. HIV high risk (discordant coup/e) cohort 
A high risk cohort of approximately 1300 HIV discordant couples was established, part 
of which was used for recruiting HIV negative female partners in a large scale phase III 
microbicide trial (Paper 10)(25). The discordant couples were identified through house-
to-house VCT surveys within Masaka town as well as clinics offering VCT services 
within Masaka district. The rationale for this new focus on higher HIV risk cohorts was 
to prepare for future HIV biomedical intervention trials that would aim to reduce the risk 
of HIV transmission. Recruitment of HIV discordant couples was therefore considered a 
possible solution to avoiding the large sample size that would be a consequence of using 
cohorts with a low HIV incidence rate. 
The purpose of these high risk cohorts was therefore to: 
• prepare the ground for intervention studies by collecting population based 
background information required to conduct large-scale clinical trials 
• assess whether participants would accept the intervention and study procedures 
prior to starting efficacy trials 
• conduct studies to evaluate the effectiveness of innovative intervention strategies 
(microbicides and HIV vaccines), among HIV negative adults living in HIV 
discordant couples 
The couples were recruited through house-to-house surveys that identified individuals in 
stable heterosexual relationships. Consenting individuals were offered couple HIV 
counselling and testing. Test results were only provided after couple counselling. The 
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HIV positive partners were provided with necessary and appropriate investigations 
(including CD4 count), as well as treatment and referral to an HIV care support 
organization of their choice for initiation of anti-retroviral treatment, if required. 
1.6.7. Vaginal microbicides 
Between 2002 and 2005 a feasibility study to assess the suitability of a discordant 
couples' cohort for a phase III efficacy trial of vaginal microbicides was conducted(26). 
The study recruited approximately 120 discordant couples identified from VCT clinics 
around Masaka town, and followed every 3 months for one year. This provided us with 
an opportunity to: (i) estimate HIV incidence; (ii) evaluate trial procedures such as the 
provision of informed consent, genital examination, acceptability of and adherence to 
the study product using a placebo gel and (iii) monitor sexual behaviour using case 
record forms, coital diaries and in-depth interviews. 
On completion of the microbicide feasibility study in 2005, a phase III international 
multi-centre, randomised, double-blind, placebo-controlled trial to evaluate the efficacy 
and safety of 0.5% and 2% PRO 200015 gels for the prevention of vaginally acquired 
HIV infection was started (Paper 10). The trial, code-named MDP 301, screened 
participants between September 2005 and August 2008 and enrolled 9385 out of 15,818 
screened at 13 clinics, which were managed by six research centres in four African 
countries (South Africa, Tanzania, Uganda and Zambia)(25). Sexually active HIV-
un infected women aged 18 years or older ＨｾＱＶ＠ years in Tanzania and Uganda) were 
randomly assigned in a 1:1:1 ratio to 2% PR02000, 0·5% PR02000, or 
hydroxyethylcellulose placebo gel groups for 52 weeks follow up (up to 104 weeks in 
Uganda). The study was conducted by the Microbicides Development Programme 
(www.mrc.ac.uk/mdp). which is a collaboration of African and European institutions. 
The MDP301 Uganda clinical site enrolled 840 HIV negative healthy women in a 
known HIV sero-discordant couple relationship. These were part of the HIV discordant 
couple cohort. The women were followed up to at least 52 weeks and to a maximum of 
104 weeks. Women were enrolled between September 2005 and August 2008. Follow-
up continued up to September 2009. Women were included if they were sexually active, 
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aged ;:::16 years, without HIV-l infection, were willing to be tested for HIV-l infection 
and receive the result, to have regular speculum examinations and urinary pregnancy 
tests, to use the allocated gel as instructed, and to receive health education about 
condoms and able and willing to give informed consent. They were ineligible if they 
were unable or unwilling to provide a reliable method of contact, were likely to move 
out of the area within 12 months, were likely to have sex more than 14 times a week on 
a regular basis (a regulatory requirement was that no more than 60 applicators were to 
be dispensed at every 4 weekly visit), used spermicides regularly, were pregnant or 
within 6 weeks post-partum, had a severe clinical or laboratory abnormality; needed 
referral for assessment of a suspicious cervical lesion, had received treatment to the 
cervix or other gynaecological procedure within 30 days of enrolment, were allergic to 
latex; or were participating or had participated in another clinical trial that was likely to 
affect the primary efficacy endpoint within 30 days before enrolment. 
1. 7. Laboratory and statistical methods 
All sera from consenting participants both in the general population and the intervention 
(high risk) cohorts were tested for HIV antibodies using two independent enzyme linked 
immunoassays to establish HIV status (Wellcozyme HIV-recombinant, Murex Biotech, 
Dartford, UK; and Recombigen HIV -112, Trinity Biotech, Galway, Ireland) with set 
algorithms and with confirmation by Western blot, (Cambridge Biotech Corporation, 
Rockville, USA)(27). We tested for sexually transmitted infections (STIs) in the various 
studies using the most recent standard assays at the time of the study. 
To estimate HIV infection rates in the general population cohort, age- and sex-specific 
prevalence was derived from the numbers of adults testing HIV positive and negative at 
each survey round. Incidence rates were calculated for all adults with an HIV negative 
result who provided a repeat blood sample on one or more occasions in subsequent 
surveys. Person-years at risk for HIV incidence commenced at the date of the initial 
HIV negative test and ceased at the date of sero-conversion. The date of seroconversion 
was calculated as the midpoint between the last negative and first positive HIV result. In 
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examining trends in HIV infection rates, analyses were conducted at three time points, 
after seven, ten and fifteen years of cohort follow up. 
Analyses for the STD/behavioural intervention trial were done separately for each of the 
intervention arms (A and B) and compared to the control arm C. The HIV incident 
events and person-years at risk of seroconversion were combined over all survey rounds. 
Analysis of STI prevalence and reported sexual behaviour at round 2 or round 3 was 
restricted to persons who had provided data for at least two survey rounds. All results 
were adjusted for potential confounders (age, sex, baseline prevalence for outcome 
measures, religion and history of genital ulcers), and analyses carried out using 
appropriate statistical methods for cluster randomized trials (CRT). 
In the MDP 301 trial, HIV status was confirmed using serum obtained up to 6 weeks 
before enrolment, at enrolment, and then at weeks 4, 12, 24, 40, and 52 (and weeks 72 
and 104 in Uganda). The HIV testing algorithm involved confirmation of all HIV 
positive results at a central laboratory in South Africa. The central laboratory analysed 
samples from the visit at which a positive serological rapid test result was obtained and 
from all previous visits at which samples were obtained. This approach was due to the 
limitations of serological assays in which a woman may already have been infected at 
enrolment but not yet positive on serological tests. The trial was designed to have 80% 
power to detect a 35% reduction in HIV incidence, assuming an incidence of 4.0 per 100 
woman-years in the placebo group. Women were censored at the date of seroconversion, 
estimated by the midpoint between the last negative test and date of detection, or at the 
last HIV-negative test for patients who did not become infected. The primary efficacy 
endpoint was analysed as time-to-event, and intervention groups were compared by use 
of hazard ratios (HRs) relative to the placebo group. Safety endpoints were analysed as 
time-to-first-event and groups compared as for the efficacy analysis. 
29 
1.8. My contribution to this research 
I was involved in setting up the rural general population cohort from the start of the 
study, and was responsible for the field activities from 1989-1993 and thereafter was 
overall team leader up to 1997. My specific responsibilities were to formulate research 
topics for each annual survey, design the necessary research tools such as 
questionnaires, supervise and ensure high quality data collection, and contribute to data 
management, analysis and publication of research findings. 
I took over the leadership and direction of the STDlBehavioural intervention trial half 
way through the study in 1997 up to 2001 when the study was completed. My tasks 
were to ensure adequate delivery of the interventions to the communities, achieve high 
follow up of the participants during the second and third survey rounds, and timely 
completion of the trial. I took the lead in ensuring data quality, initiated analyses and 
published baseline findings, process evaluation of the interventions and the final results. 
At the end of the intervention trial, I was involved in a collaborative project to explore 
the reasons for the contrasting results of the three East African STI trials(22, 28-29). 
The idea of setting up high risk cohorts of HIV discordant couples was entirely my own. 
I was the principal investigator for the HIV vaccine preparedness studies and the 
microbicide feasibility studies, and responsible for both the scientific direction and day-
to-day management of these studies. I was also the Ugandan clinical site principal 
investigator for the microbicide studies. 
1.9. Summary of findings from the publications on which 
this thesis is based 
1.9.1. H1V infection rates and trends 
The general population cohort provided the first data on HIV infection rates in rural 
Uganda and subsequently an opportunity to monitor epidemiological trends, in the 
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absence of any biomedical interventions other than health education and provision of 
STI treatment services in government health clinics using national STI syndromic 
management guidelines and discussed in Papers 1-4(12, 14, 18-19). As already 
mentioned papers 1-3 are based on data from the original 15 villages and only paper 4 
includes data from both new and old study villages. 
HIV prevalence at baseline (1989/90) among adults (13 years and above) was 8.2% with 
the highest rates occurring in women aged 20-24 years (20.9%) and in men aged 25-34 
years (18.1%)(12). Paper 1 describes seven-year trends in HIV infection rates, and 
changes in sexual behaviour(12). In paper 1, the analysis of age- and sex-specific 
prevalence was based on the number of adults testing HIV positive and negative at each 
survey round, in contrast to analyses reported in paper 2 which used imputation 
methods. HIV prevalence declined from 8.2% at baseline (1989-1990) to 6.9% in 1996-
1997 (p=0.008) with the greatest decline observed among men aged 20-24 years (11.7 to 
3.6%; p <0.001) and in women aged 13-19 years (4.4% to 1.4%; p=0.003) and 20-24 
years (20.9% to 13.8%; p=0.003). Prevalence however increased among women aged 
25-34 years (13.1 to 16.6%; p=0.04). The overall incidence declined from 7.7/1000 
person years [pyrs] (95% CI 4.9-12.2) to 4.6/1000 (95% CI 2.8-7.6) during this period, 
but neither this nor the changes in age-sex specific incidence rates were significant(l2). 
In paper 2 trends in HIV incidence and prevalence are examined using data over 10 
years (up to 1998/1999) from the same cohort(18). In this paper HIV prevalence was 
calculated using all definitive HIV serological results for each round. Individuals 
censused but not bled at a particular round were classified as HIV negative if they tested 
seronegative at a later round and positive if they had tested positive at an earlier round. 
This method of imputation enabled us to assess HIV status for some individuals who 
were censused but not bled at particular rounds. This method, however, underestimates 
the prevalence at the earliest rounds and overestimates the prevalence at later rounds. In 
particular the baseline prevalence was estimated as 8.2% (derived from data at first 
survey round) and 6.9% (using the imputation method), and the latter is likely to be an 
underestimate. 
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A significant decline in overall HIV prevalence was observed (p=0.03) especially 
among young women; from 2.8% to 0.9% in those aged 13-19 years and from 19.3% to 
10.1 % in those aged 20-24 years. In men, significant declines were seen in those aged 
20-24 years (6.5% to 2.2%) and 25-29 years (15.2% to 10.9%). However there was a 
significant rise in HIV prevalence among women aged 30-34 years (10.7% to 20.6%) 
and 35-39 years (8.3% to 14.7%); no rise in prevalence among men was observed. 
Overall HIV incidence for all adults declined from 8.0 in 1990 to 5.2 per 1000 pyrs in 
1999 (p=0.002), with an average annual reduction of about 0.45 per 1000 pyrs. A 
significant decline in incidence was observed in both females and males of all ages(18-
19). This was the first evidence of a significant decline in HIV incidence in a rural 
general adult population in Africa. 
In paper 3, HIV prevalence and incidence trends were calculated over the same 10 year 
period as in paper 2, but using cross-sectional measures for each survey round without 
extrapolating data from previous surveys (for HIV positive individuals) or subsequent 
surveys (for HIV negative individuals)(19). The observed incidence rates were similar 
to those reported in paper 2 (above) and overall prevalence as well as trends were also 
comparable to those measured using the imputation method. 
In paper 4, we analysed HIV trends over 15 years(l4). The encouraging trends in HIV 
infection observed at earlier survey rounds were no longer evident when using data over 
15 years of follow up(14). The decline in HIV prevalence was only observed up to 
1999/2000, from 8.5% in the 1990/1991 survey round (a year after baseline survey) to 
6.2% in 1999/2000. Thereafter the rate rose to 7.7% in 2004/2005. Overall HIV 
prevalence fell during the 1990s but started increasing from 1999/2000 (p=O.OI for 
significance of change in trend). Similarly, incidence fell through the 1990s, but 
between 1998 and 2004 incidence rates were no longer falling but instead there were 
indications that they were rising. 
Subjects in longitudinal cohort studies such as the MRC cohort may not participate at 
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each time point of follow up for several reasons such as absence at the time of surveyor 
research fatigue. This could potentially lead to inaccurate and biased estimates of trends 
over time. One approach to overcome this is to impute the missing data so to generate a 
more complete data set. Data on HIV status were imputed such that all individuals who 
were HIV positive at any previous survey round were classified as such at subsequent 
survey(s), if still present, irrespective of whether they were HIV tested or not. Similarly 
for individuals who were present at a given round and HIV negative, their HIV status 
was imputed as HIV negative for previous rounds if they were present but not tested. 
This approach has the advantage that it uses all available data during the entire follow 
up and provides more reliable estimates. One possible disadvantage of this method is 
that it may underestimate the prevalence of HIV-l at the earliest rounds and 
overestimate the prevalence at the later rounds since it only imputes HIV negative data 
(denominator) backwards and HIV positive data (numerator) forwards. Results from 
data analyses using imputation may differ from those using repeated cross sectional data 
analyses if the compliance rates at individual survey rounds vary greatly and also if 
there is a difference in participation between mv negative and positive individuals. We 
however noted in Papers 2 and 3 that the prevalence trends measured by both 
approaches gave similar results. 
1.9.2. HIVriskfactors 
The general population cohort provided us with an opportunity to assess risk factors for 
HIV infection in rural Africa during the early years of the epidemic. Paper 5 (based on 
data from the ten old villages) describes the sero-prevalence and incidence rates of 
Treponema pallidum. Haemophilus ducreyi and Herpes simplex Virus type-2 (HSV-2), 
and the association between HIV infection and the incidence of these STls(17). The 
sero-prevalence of T pal/idum was 12.9% among males and 12.6% among females. The 
corresponding rates for H ducreyi were 9.8% and 7.3% respectively. The prevalence for 
HSV-2 was considerably higher, 36.0% in males and 71.5% in females. We also 
observed a strongly significant association between HIV prevalence and sero-prevalence 
of H ducreyi (p=O.Ol), and HSV-2 (p=0.004) but not with T pallidum(J7}. This 
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observation was consistent with other epidemiological and biological evidence 
suggesting that STIs enhance the transmission of HIV(30-31). Incidence rates for T 
pal/idum were 8.4 per 1000 pyrs for males and 12.3 for females; the rates for H ducrey; 
were 24.6 and 20.0 and for HSV -2 were 73.2 and 122.9 per 1000 pyrs respectively. The 
rate ratio (RR) of HSV-2 incidence was 6.69 (95% CI 2.06-6.61) in initially HIV 
seropositive individuals versus HIV seronegative after adjusting for age and sex. The 
RR for H ducrey; was 3.50 (95% CI 1.29-9.46) among HIV positive females versus 
negatives but there was no effect in males. There were too few incident cases for T 
pa/lidum to make meaningful comparison. A number of other risk factors have been 
documented in this rural cohort and briefly these were: age, 13-21 years in women 
(Odds Ratio [OR] 8.6 (95% CI 3.0-24.5); marriage in those aged <25 years, OR 2.3 
(1.5-3.7); working outside one's village among those aged ｾＲＵ＠ years, OR 1.8 (1.2-2.6). 
Moslems were at lower risk than non-moslems (those aged 13-24 years, OR 0.58 (0.35-
0.95) and ｾＲＵ＠ years, OR 0.58 (1.2-2.6»(32). 
1.9.3. HIV prevention efforts 
Globally, there have been attempts to control HIV transmission and a range of 
biomedical HIV intervention strategies have been developed and evaluated through 
randomized controlled trials (RCTs) including our own STD/behavioural intervention 
trial. These include treatment of bacterial STIs, behavioural interventions, male 
circumcision, treatment of HSV -2, vaginal microbicides, Pre Exposure Prophylaxis 
(PrEP) and HIV vaccines. To date seven RCTs have shown efficacy against HIV 
transmission, of which 3 were on male circumcision which showed approximately 60% 
protection for heterosexual males(33-35). The RR (95% CI) were 0.49 (0.30-0.82) in the 
Rakai trial, 0.47 (0.28-0.78) in the Kisumu trial, and 0.40 (0.24-0.68) in the South Africa 
trial. One RCT evaluated syndromic STD case management at primary health care level 
and showed a significant reduction in HIV incidence of 42% (RR 0.58 [95% CI 0.42-
0.79])(28). Another was the Thailand HIV vaccine trial that showed modest benefit with 
an efficacy of 31.2% (95% CI, 1.1%-52:1%)(36). Two recent trials were the CAPRI SA 
004 trial that reported a 39% (95% CI, 6%-61 %) reduction using 1 % tenofovir vaginal 
microbicide gel(37) and the iPrex trial using oral Truvada among men who have sex 
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with men (MSM) that demonstrated a 44% (95% CI, 15%-63%) reduction in HIV 
incidence(38). 
The HPTN052 trial looking at ARV treatment as prevention among ART na'ive patients 
with a CD4+ cell count of 350-550 cells/mm3 in a number of countries has recently 
reported a 96% reduction in the risk of HIV transmission to the uninfected partner 
among HIV serodiscordant couples (www.hptn.org). 
In paper 6 we describe the trial design, methods and baseline findings of the 
STDlbehavioural intervention trial(2I). In summary, the study design was a three-arm 
community randomized trial of 18 rural communities. The intervention was targeted at 
the resident population (96,000 adults). Impact assessment of the interventions was 
through three questionnaire and serological surveys conducted at 18-24 months 
intervals. The required survey sample size for impact evaluation in each arm was 4500 
adults (750-1000 adults in each community). Obtaining this number required our 
surveying 3-5 villages closest to a health unit. It was necessary to survey whole villages 
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and not part of a village. Out of approximately 20,000 resident adults in the survey 
villages, 14,500 (72%) were enrolled for the impact assessment. Of those enrolled 97% 
were both tested for HIV and interviewed at baseline. The primary outcome measure 
was HIV incidence and secondary measures were syphilis and Herpes simplex virus 
type-2 (HSV-2) incidence, prevalence of Neisseria gonorrhoeae and Chlamydia 
trachomatis, and reported sexual behaviour. HIV baseline prevalence ranged between 
8.8% in arm A and 10.4% in arm C. The demographic and behavioural characteristics 
were also similar. There was little variation between arms in STD prevalence for active 
syphilis (range 10.8%-14.8%), HSV-2 (range 27.9%-28.4%), gonorrhoea (range 1.1%-
1.4%) and Chlamydia (1.5%-2.0%)(21). 
Paper 7 discusses the main results of the STDlbehavioural intervention trial. In 
summary the HIV incidence did not differ between the behavioural intervention (group 
A) and comparison groups (group C) or between the STD intervention (group 8) and 
comparison groups even after adjusting for various covariates(22). Compared to the 
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comparison arm the incidence rate ratios (in brackets 95% CI) of HI V were 0.94 (0.60-
1.45) in group A and 1.00 (0.63-1.58) in group B, and the corresponding prevalence 
ratios for condom use with last casual partner were 1.12 (0.991.25) and 1.27 (1.02- 1.56) 
respectively(22). 
In paper 8, we did further analyses of these results which indicated that although the 
behavioural intervention had no significant benefit in the communities as a whole, it 
resulted in a reduced risk of HIV acquisition among women who attended at least one 
intervention activity compared to those who attended none (adjusted rate ratio 0.41 
[0.19-0.89])(23). 
At the end of the trial comparative analyses were conducted using data from this trial 
and those from two other similar trials in the region, the Mwanza syndromic STI and 
Rakai STI mass treatment intervention studies(39-40). 
1.9.4. Preparations for future HIV prevention efficacy trials 
As HIV transmission continues especially in low-income countries, the development of 
new prevention methods such as HIV vaccines and microbicides is a high priority for 
research even in the era of ART rollout. In preparation for these efficacy trials, 
feasibility studies were initiated to assess the suitability of population cohorts. It was 
necessary to assess whether such cohorts would provide sufficiently high HIV incidence 
rates for inclusion in efficacy trials, and to examine the retention and willingness to 
participate in these cohorts. In Paper 9 we assessed willingness to participate in HIV 
vaccine efficacy trials as well as motivations, concerns, and barriers to participation 
among volunteers completing two years of follow up in a HIV vaccine preparedness 
study in the general population, in communities with high HIV prevalence(24). A high 
level of willingness to participate in such trials was observed. The key motivating 
factors were: hope of being protected from HIV (47%), access to regular HIV 
counselling and testing (36%) and altruism (28%). However a number of trial 
requirements (delayed pregnancy among women, giving large volumes of blood) were 
associated with reduced Willingness to participate(24). 
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1.9.5. Vaginal microbicide prevention trial 
Paper 10 discusses the results of the Microbicide Development Programme (MOP) 
phase III trial of the 0.5% and 2% PRO 200015 vaginal microbicide gels(25). This was a 
multi-centre trial in 4 African countries, with Masaka district in Uganda as one of the 
sites. Participants were instructed to apply a single dose of study gel up to one hour 
before every act of vaginal intercourse using a single-use, pre-filled applicator (the study 
gel contained either the microbicide or a placebo, depending on the arm of the trial). 
Participants received free condoms and risk-reduction counselling, regular health 
checks, sexually transmitted disease testing and treatment, and referral for HIV 
treatment where appropriate. The primary outcome measures were HIV infection and 
grade 3 (severe) or 4 (life-threatening) adverse events. The secondary outcomes 
included HSV-2, Neisseria gonorrhoeae and Chlamydia trachomatis infections. 
Overall gel adherence in the trial was high (mean reported gel use at last sex act was 
89%) and did not differ between the three gel arms. Reported condom use at last sex act 
increased over time from 57% at enrolment to 88% at week 52 of follow up, and was 
similar across gel groups though there was variation between research centres. HIV 
incidence (primary outcome) was similar between groups at the end of the study- 4.5 per 
100 woman years (95% CI 3.8-5.4) in the 0.5% gel arm and 4.3 (3.6-5.2) in the placebo 
arm, HR 1.05 (0.82-1.34), p=0.71. The Data Safety Monitoring Committee of the trial 
had earlier recommended discontinuation of the 2% gel arm due to futility. At the time 
of the 2% arm closure, HIV incidence was 4.7 (3.8-5.8) in the 2% gel arm, 3.9 (3.0-4.9) 
in the 0.5% gel arm and 3.9 (3.1-5.0) in the placebo arm. The primary safety endpoint 
was a grade 3 (severe) or worse clinical or laboratory adverse event. The rates of safety 
endpoints did not differ between study arms either at the end of the study or at the time 
2% gel was discontinued. Both PRO 2000 gel concentrations were safe but not effective 
against vaginal HIV transmission. 
In the following chapters I shall critically examine epidemiological trends of HIV 
infection in Uganda, the key determinants of these trends and strategies that could 
prevent HIV in this population. To this end, I shall introduce some new material that 
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was not included in the original, published papers. 
1.10 Key determinants of HIV incidence and prevalence 
There are a number of key determinants for HIV sexual transmission that are broadly 
categorised into socio-economic and cultural (income, education, occupation, religion 
and ethnicity), demographic (sex, age, marital status, mortality and migration), 
behavioural and biological. The socio-economic, cultural and demographic factors can 
often be viewed as underlying determinants of HIV transmission whereas the 
behavioural and biological factors are those that directly determine the rate of new 
infections (exposure of susceptible to infected person, transmission probability per 
sexual contact and duration of infectiousness). 
Because of the complexities of these multiple factors, and their inter-relations, a 
proximate-determinants framework used in demographic studies (fertility and child 
survival), has been suggested to help in understanding the drivers of HIV transmission 
and how they relate to each other (41). Briefly, the framework suggests that the 
underlying determinants (eg age, sex, marital status, etc) influence the risk of 
transmission through proximate (ie behavioural and biological) determinants such as the 
presence of other sexually transmitted diseases, sexual mixing and concurrent 
partnerships, condom use, antiretroviral treatment, and lack of circumcision among men. 
Without such linkage the underlying factors would not on their own affect HIV 
transmission. Based on the published papers included in this thesis, the following 
underlying and proximate determinants have been examined to understand HIV trends 
in this cohort: 
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Underlying determinants 
Age 
Sex 
Marital status 
Migration 
Mortality 
Proximate determinants 
Number of sexual partners 
Age at first sex 
Condom use 
Antiretroviral treatment 
Previous analyses of data from this cohort have also looked at other determinants such 
as socio-economic factors, lifetime sexual partners, and religion. Briefly there was 
evidence of increased risk of HIV infection with poverty among heads of households, 
greater number of sexual partners (more than four), and not being a Muslim suggesting a 
possible protective effect of circumcision( 42-43). 
It has not been possible to examine other determinants due to the nature of the study 
design that assessed HIV infection through annual house-to-house surveys. These 
include determinants that facilitate sexual exposure to HIV (frequency of sex acts, 
sexual mixing with different population patterns); and those that enhance transmission 
(sexual practices e.g anal sex, circumcision status, presence of STIs and their treatment). 
This would have required additional data collection, for example on presence of 
sexually transmitted infections and infectiousness of infected partners (viral load) or 
more in-depth social science techniques, that were not feasible in the context of this 
research. Contributions of other determinants (blood transfusion, injection drug use, 
unsafe injections) have also not been examined because of epidemiological evidence 
that these modes of transmission do not play a major role in HIV epidemic in this 
setting( 44-45). 
Other limitations with the approach used here are related to the well known reporting 
biases associated with sexual behaviour data collection. In addition some of the data 
were not systematically collected at every survey and not on all sexually active 
individuals. For example, selected sensitive questions on sexual behaviour were 
incorporated in some annual survey rounds, but were not repeated in all rounds due to 
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fear of research fatigue that could report in greater reporting bias. Retrospective 
application of this framework to existing data is another limitation in that data on some 
important parameters were not collected or are difficult to assess particularly the 
underlying determinants such as social, economic and environmental factors that are 
linked to HIV transmission through their effects on proximate behavioural and 
biological determinants. 
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Chapter 2. Trends in HIV incidence and prevalence 
Summary 
This chapter examines trends in HIV prevalence and incidence in Uganda and considers 
possible explanations for these trends. Overall HIV prevalence was higher for females 
than males in all years in the MRC cohort. The prevalence declined in both men and 
women between 1990 and 2000 but rose between 2000 and 2008. The decrease 
between 1990 and 2000 was particularly pronounced for those aged 20-24 years. 
However, for those aged 35 years and above, a steady increase in HIV prevalence was 
observed among females and males throughout the study period (1990-2008). Various 
reasons for these age and sex differences in HIV prevalence are explored in the chapter. 
Trends in HIV incidence rates in the MRC cohort were less clear than the trends in HIV 
prevalence. Overall HIV incidence (all ages) declined significantly between 1990 and 
2008 (p=O.OO I). The decline in incidence was significant between 1990 and 2000 
(p=O.OI) although there was a non-significant increase from 2001 to 2008 (p=0.34). A 
decline in HIV incidence was seen from the early 1990s, indicating that the decline 
could have started earlier, possibly in the late 1980s. 
I used a proximate determinants framework to better understand trends in HIV 
prevalence. A net outflow of HIV positive migrants, more deaths of HIV positive 
individuals and reductions in risky sexual behaviour in the 1990s seem to have been 
important factors in explaining the decline in HIV prevalence during that decade. The 
increase in prevalence since 2000 is not fully understood. Improved survival due to 
ART, the "normalization" of HIV/AIDS and possible complacency around safer sex 
could have led to an increase in risky sexual behaviour. 
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2.1. Introduction 
This chapter examines trends in HIV prevalence and incidence rates in Uganda during 
the study period (1989-2008), considers possible determinants of these trends and 
compares them with trends in two other countries in East and Southern Africa. 
For this chapter I have conducted additional analyses by extending the analysis to 2008. 
I have applied imputation of data from all survey rounds by extrapolating data from 
previous surveys for HIV positive individuals and from subsequent surveys for HIV 
negative individuals. As a consequence there are minor discrepancies between the 
estimates presented in this chapter and the point estimates in chapter 1 which are based 
on the published papers and analyses conducted at the time the papers were written. In 
this chapter, I have used four age groups (13-19, 20-24, 25-34 and ｾＳＵＩ＠ for describing 
the age and sex-specific HIV prevalence trends. Due to relatively small numbers 
incidence trends have not been analysed by age group. 
Uganda was one of the earliest countries in Africa to report the new epidemic of HIV 
when Serwadda and colleagues first reported the spread of "Slim Disease" along the 
shores of Lake Victoria in 1982(15). The epidemic that started silently spread rapidly 
across the country mainly along the trans-African and other major highways. Due to 
civil unrest at the time there were no prevention efforts until 1987 when the first HIV 
prevention programme was started through the National AIDS Control Programme. 
However this was at a time when the country was already facing a major epidemic. The 
first published HIV prevalence data in Uganda indicated a prevalence rate in the early 
1990s of 30-40% in urban areas(46) and around 8-10% in rural districts(32, 47). 
As summarized in chapter one, data from the MRC cohort study on which this thesis is 
based indicated that HIV prevalence rates fell during the 1990s(19). However this 
decline was no longer evident from 2001(14). In this chapter, I describe in more detail 
trends in HIV prevalence and incidence among those individuals residing in the old 
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villages that participated in annual surveys of the MRC cohort from 1990 up to 2008 as 
well as examining data from other sources. Specifically, I examine: 
• trends in HIV prevalence by age and sex in the MRC cohort as well as HIV 
prevalence at a national level; 
• trends in HIV incidence by sex in the MRC cohort and HIV incidence estimates 
from other sources in Uganda; 
• trends in sexual behaviour in the MRC cohort as well as in other studies; 
• possible explanations for the time trends in HIV prevalence; 
• possible explanations for the age-sex differences in HIV prevalence 
• HIV prevalence trends in two other African countries. 
2.2. HIV prevalence 
2.2.1. Time trends in HIV prevalence in the MRC cohort 
Little was known about HIV/AIDS in Uganda and in many other parts of sub Saharan 
Africa prior to the mid-1980s. This was because of low awareness, fear of being tested 
for HIV and stigma. Most people with HIV were only reported near the time of death. 
Data on HIV/AIDS initially came only from urban hospitals in large cities. National 
surveillance systems were non-existent and there were no community based studies on 
HIV. Consequently no reliable data on time trends in HIV prevalence were available 
before 1990. 
Using data from the rural population cohort of the MRC Programme, we found that 
overall HlV prevalence declined in both men and women between 1990 and 2000, from 
6.5% to 6.2% (p value for trend <0.01) and from 7.9% to 7.7% (p value for trend <0.01), 
respectively (table 2.1 and figure 2.1). Trend analysis for HIV prevalence over the 
entire study period (1990-2008) ind icates a significant decline among men (p for trend < 
0.001) but a non significant decline among women (p for trend = 0.29). In all years HIV 
prevalence was, overall, higher for females than males. 
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An initial rise in prevalence was observed up to 1993 followed by a decrease thereafter. 
The decline in HIV prevalence that started in 1993/4 continued up to 2000/1, an 
encouraging observation that contributed to the Uganda "success story" through the 
1990s. Between 2001 and 2008, prevalence increased from 5.9% to 6.5% (p value for 
trend =0.5) in males and from 7.4% to 9.7% (p value for trend <0.01) in females. 
Overall HIV prevalence remained higher for females than males in all years. 
Table 2.1 HIV prevalence by gender (1990-2008) with 95% CI 
Males Females 
Survey HIV+ N Prev (%) 95% CI HIV+ N Prev (%) 95% CI 
1990 149 2278 6.54 5.53-7.56 191 2416 7.91 6.83- 8.98 
1991 177 2335 7.58 6.51-8.65 239 2568 9.31 8.18-10.43 
1992 178 2366 7.52 6.46-8.59 239 2555 9.35 8.23-10.48 
1993 189 2375 7.96 6.87-9.05 238 2536 9.38 8.25-10.52 
1994 174 2361 7.37 6.32-8.42 216 2571 8.4 7.33- 9.47 
1995 165 2364 6.98 5.95-8.01 221 2538 8.71 7.61- 9.80 
1996 146 2370 6.16 5.19-7.13 202 2566 7.87 6.83- 8.91 
1997 155 2446 6.34 5.37-7.30 213 2657 8.02 6.98- 9.05 
1998 153 2578 5.93 5.02-6.85 220 2796 7.87 6.87- 8.87 
1999 155 2645 5.86 4.97-6.76 232 2928 7.92 6.95- 8.90 
2000 170 2744 6.2 5.29-7.10 236 3078 7.67 6.73- 8.61 
2001 164 2799 5.86 4.99-6.73 230 3108 7.4 6.48- 8.32 
2002 159 2707 5.87 4.99-6.76 238 3058 7.78 6.83- 8.73 
2003 158 2725 5.8 4.92-6.68 230 3076 7.48 6.55- 8.41 
2004 150 2690 5.58 4.71-6.44 242 3070 7.88 6.93- 8.84 
2005 147 2565 5.73 4.83-6.63 240 3027 7.93 6.97- 8.89 
2006 146 2473 5.6 4.71-6.50 251 3007 8.35 7.36- 9.34 
2007 146 2473 5.9 4.97-6.83 257 2984 8.61 7.61-9.62 
2008 152 2328 6.53 5.53-7.53 283 2918 9.7 8.62-10.77 
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Figure 2.1 HIV prevalence by gender (1990-2008) 
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2.2.2. Age alUl sex differences il1 HIV prevalence ill tile MRC collort 
Figures 2.2 and 2.3 show trends in HIV prevalence by age and sex. Prevalence among 
young men aged 13-19 years remained generally low and stable (below 1.0%) 
throughout the study period. Among men aged 20-24 years there was a significant 
decline from 8.7% in 1990 to 1.9% in 2000 (p value for trend <0.00 I) and thereafter a 
non-significant rise to 2.3% in 2008 (p value for trend=0.47). A decline was also 
observed among those aged 25-34 years, from 15.9% in 1990 to 14.2% in 2000 (p va lue 
for trend =0.002) fo llowed by further decline to 10.4% in 2000 though non-significant. 
In men aged 35 years and above however, there was a borderline significant increase in 
prevalence from 6.7% in 1990 to 9.7% in 2000 (p value=0.05) and thereafter a non-
sign ificant rise from 9.1 % to 11.5% in 2008 (p va lue for trend = 0.12), reaching the 
same level as in those aged 25-34 years. 
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Figure 2.2 HIV prevalence by age among males (1990-2008) 
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Figure 2.3 HIV prevalence by age among females (1990-2008) 
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Prevalence in women aged 13-19 years declined from 3.9% to 1.1% (p value for trend 
<0.001) during the 1990s and then increased up to 1.7% in 2008 (p value for trend < 
0.001). Despite very high prevalence among women aged 20-24 years at baseline (figure 
2.3) there was an encouraging decline from 19.0% in 1990 to 10.7% in 2000 (p value for 
trend <0.001) with a significant increase in the 2000s (from 8.1% in 2001 to 10.0% in 
2008). In women aged 25-34 years, however, there was an increase in prevalence during 
the 1990s from 12.1 % at baseline to 18.4% in 2000 which was significant (p value for 
trend =0.005). Thereafter the rates remained fairly stable in this age group through the 
2000s. The trends among women aged 35 years and above have probably been the most 
discouraging with no decline but rather a steady and significant rise during both periods 
(p value for trend < 0.001). This was clearly the opposite of what was seen among those 
aged 20-24 years. The rates among women aged 35 years and above reached the same 
level as those aged 20-24 years by 2006 (figure 2.3). 
In all years of follow up, HIV prevalence among females aged 13-19 and 20-24 years 
exceeded that of males. A female excess was also seen among those aged 25-34 from 
1996 onwards. Among those aged 35 years and above, prevalence was similar for males 
and females 
In summary, overall HIV prevalence for both men and women declined significantly in 
the 1990s. During the 2000's the trends in men were less clear though there seemed to be 
an indication of stabilization at all ages. In women there was an overall significant 
increase (all ages combined and in those aged 35 years and above) but no increase for 
younger age groups. The decline in the 1990s was particularly marked for men aged 20-
34 years and women aged 20-24 years. Among those aged 3S years and above, a steady 
increase in HIV prevalence in both females and males was observed throughout the 
study period, and this was significant among males in the 1990s and women in the 
2000s. In general HIV prevalence was higher among females than among males of the 
same age, although this was not so apparent among the over 35s. 
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2.2.3. HIV prevalence at a national level 
At a national level the analysis of HIV prevalence trends revealed three distinct phases; 
initially a phase of rapid increase between 1989 and 1992 with prevalence peaking at 
about 18%, followed by a rapid decline between 1992 and 2002 and finally a phase of 
stabilization at about 6.1-6.5% between 2002 and 2005(48}. The trends in HIV 
prevalence observed within our cohort have been seen in other studies in Uganda such 
as the Rakai Programme cohort and the antenatal surveillance monitoring system of the 
Ministry of Health. HIV prevalence in the Rakai cohort showed a significant decline 
between 1994/1995 and 2002/2003 in those aged 15-49 years, from 19.7% to 12.9% (a 
34% reduction) among women and from 15.0% to 9.3% (a 38% reduction) among 
men(49}. In the antenatal clinics, HIV prevalence trends in Northern Uganda showed a 
significant decrease from 26.0% in 1993 to 16.1 % in 1997 (p <0.001). The decrease was 
more pronounced among women below 30 years (p <0.001) in both rural and urban 
areas(50). From the surveillance system established in Uganda in 1989, data from six 
urban antenatal sentinel sites (two in Kampala and four from other major towns) 
indicated that overall prevalence in all clinics peaked at 15-30% in 1991-92, followed by 
a decline to 5-12% by 2002; this decline was seen mainly among women aged 15-19 
and 20-24 years. In Kampala-based clinics alone, antenatal HIV prevalence declined 
from 30% in 1992 to 8.3% in 2002(51}. Data from the 2004-2005 National Sero-
Behavioural Survey indicated overall prevalence of 6.4% and 6.3% among those aged 
15-49 and 15-59 years respectively. These studies reflect the overall downward trend 
in HIV prevalence reported by the MRC cohort between 1990 and 2000, although the 
evidence for a subsequent increase during the 2000s is less clear. 
2.3. HIV incidence 
2.3.1. Time trends in HIV incidence in the MRC cohort 
Data on HIV incidence rates are more useful in tracking the epidemic, as well as 
evaluating interventions, than HIV prevalence since incidence rates give an indication of 
the current course of the epidemic. The trends in incidence rates observed from 1990-
48 
2008 in the MRC cohort are less clear than prevalence trends mainly because the 
incidence estimates are based on smaller numbers of HIV seroconversions than the 
numbers of HIV infections used to estimate prevalence. Because of small numbers, two-
year incidence estimates have been computed to monitor the trends in the MRC cohort 
(table 2.2 and figure 2.4). Even using this approach, the confidence intervals around 
these estimates are very wide. Overall the incidence (all ages) decreased from 7.5 in 
1990 to 6.4 per 1000 pyrs in 2008 (p=O.OOI). The decline in incidence was significant 
between 1990 and 2000; from 7.5 to 4.6 per 1000 pyrs (p=O.OJ). However there was a 
non-significant increase from 2001 to 2008 (5.8 to 6.4 per 1000 pyrs, p=0.34). In men 
incidence rates declined from 9.2 per 1000 person years (pyrs) in 1990 to 5.4 per 1000 
pyrs in 2000 (p=0.17), and from 4.6 in 2001 to 3.5 per 1000 pyrs in 2008 (p=0.31). The 
rates among women declined from 5.9 in 1990 to 4.0 per 1000 pyrs (p=O.04) in 2000. 
The corresponding rates between 2001 and 2008 were 6.8 to 6.5 (p=0.62) respectively. 
The decline in incidence seen from the early 1990s could be an indication that the 
decline could have started earlier, possibly in the late 1980s. This decline continued 
through the early 2000s. 
Earlier analyses of annual incidence rates from this cohort had indicated that HIV 
incidence declined steadily for all adults from 8.0 per 1000 pyrs in 1990 to 5.2 per 1000 
pyrs in 1999, p=0.002(14, 18-19). The declining trend was observed in both females and 
males of all ages as well as in specific age groups (13-34 years and those aged above 35 
years). 
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Figure 2.4 HIV incidence rate by gender 1990-2008 
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Table 2.2 HIV incidence rate by gender 1990-2008 with 95% CI 
Males Females 
Period Cases pyot Inc/1000 95%CI Cases pyot Inc/1000 95%CI 
1990 10 1082.6 9.23 4.97-17.17 7 1187.6 5.89 2.81- 12.36 
1991 /92 23 36 13.3 6.37 4.23-9.58 19 3867.6 4.9 1 3. 13 -7.70 
1993/94 17 38.56.7 4.4 1 2.74-7.09 4 1 4 106.3 9.99 7.35-13 .56 
1995/96 3 1 4 151.7 7.47 5.25- 10.62 30 4457.0 6.73 4.71 -9.62 
1997/98 19 4397.8 4.32 2.76-6.77 2 1 47 15.0 4.45 2.90 -6.83 
1999/00 26 4804.6 5.4 1 3.68-7.95 2 1 5230.0 4.02 2.62 -6 .1 6 
2001 /02 22 4778.9 4.6 3.03-6.99 36 5265.5 6.84 4.93 -9.48 
2003/04 15 4762.8 3.1 5 1.90-5.22 30 5336.6 5.62 3.93 -8.04 
2005/06 II 45 17.6 2.44 1.35-4.40 20 5195.8 3.85 2.48 -5.97 
2007/08 14 4028.5 3.46 2.06-5 .87 3 1 4798.0 6.46 4.54 -9. 19 
t Person-years (PYO) 
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Whereas HIV prevalence rates among males were significantly lower than in females 
throughout the study period, we did not see any sex differences in incidence. This 
discrepancy is rather surprising, as it would be expected that women would have higher 
incidence due to behavioural and biological factors that predispose women to greater 
HIV susceptibility (see 2.6.1). One possible explanation could be that when we began to 
monitor trends in HIV incidence in this cohort (late 1989), incidence rates had already 
started declining. Women may have had a higher incidence than men until the early 
1990s which could explain their higher prevalence subsequently. Thereafter incidence 
rates are likely to have been too low in both sexes to be able to detect any male-female 
differences. On average the number of incident cases in the MRC cohort was 
approximately 22 cases annually in both sexes. With such small numbers it would be 
difficult to detect any sex difference in incidence even when data over time periods are 
combined. 
The trend analyses have been carried out for two time periods, the 1990s and 2000s. 
This approach was taken for a number of reasons. We had already used similar cut off 
points in some of the previous published papers in which we reported a decline from 
1990 to 2000 and thereafter a rise from 2000 to 2005(14, 19). Similar periods have also 
been used in other studies that have described trends in HIV prevalence in Uganda(52). 
Secondly it appeared logical to analyse the trends during the first 10 years of the study 
and then compare with later years. The first ten years was a period when there were 
intensive national HIV prevention campaigns which, together with effects resulting from 
deaths of relatives, friends and in wider communities, could have resulted in reductions 
in risk behaviour. On the other hand, there were reports of complacency for HIV 
prevention at individual and organizational levels in the later years during the 2000s. 
Antiretroviral treatment became available in mid 2000s and may also have contributed 
to complacency. 
I acknowledge that the periods chosen for these trend analyses could he considered as an 
arbitrary choice of cut off dates and possible alternative periods could be used. There are 
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also other alternative approaches that future analyses could consider, such as change-
point analysis. This is considered to be an effective and powerful statistical tool when 
analysing historical data and detennining if and when a change in a data set has 
occurred. This method characterises the changes, controls the overall error rate and 
provides a confidence level that indicates the likelihood of the change(53). 
2.3.2. HIV incidence data/rom otller sources 
Data on trends in HIV incidence in Uganda have only been available from two 
longitudinal cohorts - the MRC cohort and the Rakai cohort. The first evidence of 
falling HIV incidence in Uganda was provided by data from the MRC cohort over the 
10-year period 1990-2000( 14, 18-19). Data from the Rakai cohort however showed that 
there was no significant decline in HIV incidence in men and women aged 15-49 years 
or in young adults aged 15-24 years between 1994/1995 and 2002/2003(49). The 
reasons for this discrepancy between these two studies, carried out in neighbouring 
districts, are not clear though it is possible that the epidemic is older in Rakai than in 
Masaka district. Rakai district which borders Tanzania is where the first AIDS cases 
were identified and has been thought to be the initial epicentre of the HlV/AIDS 
epidemic in Uganda. It is therefore possible that the peak of HI V incidence in Rakai was 
some years before Masaka and by the 1990s the decline had levelled off. 
In summary, trends in HIV incidence rates are less clear than those for HIV prevalence. 
For all adults we observed a significant decline in HIV incidence rates in the 1990s and 
a non-significant increase from 2001. The declines seen in men during the two time 
periods were not significant. In women there was a borderline significant decline in the 
1990s and a non significant increase in the 2000s. These observations could be related to 
the stage of the HlV epidemic in Uganda and clearer patterns could possibly have been 
found earlier in the epidemic before surveillance of this cohort began. It is not yet clear 
if incidence is now increasing, because of the small annual number of HIV 
seroconversions. 
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2.4. Trends in sexual behaviour 
2.4.1. Data/rom tile MRC collort 
It is important to examine whether trends in HIV infection may be explained by trends 
in behaviour in the same population. I will focus mainly on specific behavioural factors 
that have been demonstrated to be associated with HIV risk in previously published 
work based on data from the same rural MRC general population cohort. We observed 
that HIV prevalence was associated with reported number of lifetime sexual partners but 
not with number of partners in the past 12 months. HIV prevalence increased with 
number of lifetime sexual partners, with an OR of 2.1 among those with 4-10 partners 
and 4.9 among those reporting ｾ＠ 11 partners(42), compared with those reporting 1-3 
partners (p <0.001). Similarly, we observed that the strongest risk factor for HIV 
incidence in this same cohort was lifetime sexual partners. A significantly higher risk of 
HIV infection was observed in both men (OR 3.8) and women (OR 20.8) with ｾＵ＠
lifetime sexual partners compared to those who reported at most one partner(54). 
HIV transmission in sub-Saharan Africa is predominantly heterosexual and changes in 
sexual behaviour contribute to epidemiological trends in HlV infection. Collection of 
sexual behaviour data started in survey round 4 (1992/3). We avoided asking sensitive 
sexual behaviour questions in early survey rounds as there was not sufficient research 
capacity but also to initially build community confidence in the research team. In 
addition, we did not ask all sexual behaviour questions at every survey. This was to 
reduce fatigue among study participants and hopefully to avoid misreporting on 
sensitive questions, if asked annually. For example, age at first sex was asked in 1992/3 
(round 4) and thereafter annually. Data on condom use at last sex were first collected in 
1992/3, then in 199617, 1997/8, and annually from 1999 to 2001, and then in 2003,2005 
and 2006. 
Initial analysis of sexual behaviour data from the cohort indicated that risky sexual 
behaviour dec\ ined in the late 1990s( 12). A comparison of sexual behaviour at survey 
rounds 4 and 8, when age at first sex was asked, indicated that the median age at first 
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sex among young men aged 13-19 years was 17.5 years in 1992/3 compared to 18.2 
years in 199617 (p value for trend =0.002) (figure 2.5). However median age at first sex 
among young women aged 13-19 years did not change over that time (16.7 years in both 
survey rounds, p value for trend=0.2). There was also a significant decrease in the 
annual age-specific prevalence of being married for young women aged 16-19 years (p 
value for trend <0.001). This was particularly so between 18 and 19 years. There was no 
change in age at first marriage for men. The median age at both survey rounds was 24 
years for men (figure 2.6). 
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Figure 2.5 Percentages who reported ever having sex in survey rounds 4 and 8 ages 13-
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Figure 2.6 Percentages who were married in survey rounds 4 and 8 ages 13-19 
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Another paper from this cohort described sexual behaviour between 1993 and 2006(55). 
Briefly there were trends towards safer sexual behaviour in the late 1990s and early 
2000s among teenagers and young adults. Among those aged 17-20 years, reported 
median age at first sex increased by almost a year from 17.8 years to 18.6 years between 
1997 and 2006 (p for trend, 0.001). Among girls it increased from 16.7 to 18.2 years and 
among boys from 18.5 to 19.9 years. The proportion of 13-19 year olds who reportedly 
had never had sex increased from 71.7% in 1993 to 82.6% in 2006. In addition there 
was an increase in secondary abstinence (defined as being sexually active at least once, 
but to have not been sexually active in the past year) in the 13-19 year olds in both boys 
and girls but no change in other age groups. Similarly there was an increase in age at 
first marriage among both women and men aged 13-29 years from 19.0 to 19.4 years 
and from 24.9 to 25.3 years respectively. In general, these trends in sexual behaviour 
among teenagers and young adults reflected HIV prevalence trends in the same period 
for this age group. 
The rate of condom use also increased significantly between 1992/3 and 199617 (figure 
2.7). The overall proportion who had ever used condoms increased in males from 12.5% 
to 35% during the five year period (p value for trend <0.001) and in females from 4% to 
12% (p value for trend <0.001), with significant increases for all age groups under 35 
years (figure 2.7). The observed trends towards increase in ever using a condom 
continued up 2006: in men from 35% in 1996/7 to 46.1 % in 2006. The corresponding 
rates among women were 12% and 30.7% respectively. 
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Figure 2.7 Reported use of ever using condoms by sex and age at survey rounds 4 
(1992/3) and 8 (1996/7) with 95% CI (restricted to those ever having had sex) 
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Condom use at last sex act with any partner decreased in men from 18.9% in 1996 to 
15.3% in 2000 and 14.7% in 2003, and then increased to 15.6% in 2005 and 18.1 % in 
2006 (p for trend <0.001). Among women the rates were 5.7% in 1996 increasing to 
8.6% in 2000, then a decrease to 8.0% in 2003 and 7.6% in 2005, followed by an 
increase to 9.9% in 2006 (p for trend =0.71). Among married people who reported any 
casual partner in past year, condom use at last sex with casual partner was 67% in 1997 
(when question was first asked), 50% in 2000, 55% in 2003 and 59% in 2005 (data not 
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available in 2006), p for trend =0.02. The rates in men were 71 % in 1997, 59% in 2000, 
61 % in 2003 and 63% in 2005. Married women who reported a casual sex partner were 
less likely to use a condom at last sex (40% in 1997,8% in 2000, 24% in 2003 and 38% 
in 2005). The sex-specific trends in condom use at last sex with a casual partner among 
married people were not significant. There was an overall drop in proportion of married 
people reporting condom use at last sex with a casual partner in 2000 especially among 
women. It is possible that these were underestimates. Trends of sexual behaviour using 
data on numbers of sexual partners from the cohort were not consistent during the study 
period to make any meaningful interpretation. 
The research team provided HIV testing and counselling to the residents in the study 
area as well as continuous health education. This was in addition to the National AIDS 
control programme activities. Any decline in risky behaviour in our cohort could 
therefore have been a result of the national control efforts of HIV -specific health 
education from governmental and non-governmental sources and in the media (private 
local radio stations and newspapers) as well as MRC research activities. 
2.4.2. National data 
Data on sexual behaviour from the Uganda national Demographic Health Survey (DHS) 
conducted in 1988/89, 1995 and 2000/01 indicate that the median age at first sex among 
women increased from 16.5 years in 1989 to 17.3 years in 2000, and among men from 
17.6 years in 1995 to 18.3 years in 2000. In addition the proportion of those reporting 
premarital sex and multiple sex partners among women decreased between 1995 and 
2000 though there were no changes in reported extramarital sex among men(51). 
Comparison of 2000101 and 2004/5 DHS indicated that the median age at first sex 
among those aged 20-24 increased among women from 16.7 to 17.1 years, and declined 
among men, from 18.8 to 18.3 years. 
Trends in sexual behaviour observed in the DHS (1989, 1995 and 2000) suggested a 
shift towards less risky behaviour(56). The percentage of people who reported ever 
using a condom gradually increased in both women and men from 1989 to 2000. Among 
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women (aged 15-49 years) it increased from 1% to 16% and in men (aged 15-54 years) 
from 16% to 40%. 
2.4.3. Summary of trends in sexual behaviour 
In summary, there was a trend towards less risky sexual behaviour between 1990 and 
2000 in the MRC cohort which continued up to 2006 particularly in young adults. There 
was an increase in median age at first sex in males, in the proportion of those who 
reportedly had never had sex and in secondary abstinence in both males and females. 
We also observed an increase in age at first marriage in both sexes aged 13-29 years. 
The trends in condom use are less clear. The findings from the Uganda DHS between 
1989 and 2005 also indicated trends towards less risky behaviour. 
2.5. Explaining time trends in IIIV prevalence in Uganda 
2.5.1. Factors that can influence HIV prevalence 
Understanding how HIV prevalence changes from one survey to the next in the MRC 
cohort is complex, because it depends on a number of factors. HIV prevalence could 
increase for the following reasons: an increase in the number of people sero-converting 
from the previous round (increase in incidence); an increase in survival due to 
improvements in treatment; an increase in the number of HIV -positive people moving 
into the area (in-migration); an increase in the number of people who have never 
previously tested testing positive (reducing the undiagnosed fraction). On the other 
hand, HIV prevalence could decrease from one round to another because of the death of 
prevalent cases, because of HlV-positive people leaving the area (out-migration) or 
because of a decrease in HlV incidence. I will explore underlying determinants such as 
migration and mortality as well as proximate determinants such as reported sexual 
behaviour in trying to explain the trends in HIV prevalence observed during the study 
period. 
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2.5.2. Increasing HIV prevalence 1990-1993 
The increase in HIV prevalence during the initial survey rounds (1990-1993) was 
largely due to the in-migration of people with HIV infection as well as people newly 
testing for HIV (figure 2.8). 
Figure 2.8 Contributions to HIV prevalence numerator 
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In 1990, health services in rural Uganda were generally inadequate whereas the M RC 
Programme was offering free treatment to study participants. Consequently, seriously ill 
patients, many of whom could have been HIV infected, returned to their natal home 
from urban and neighbouring areas to access treatment that was being offered at no cost 
to study participants. 
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In addition the MRC research group was new to the area in 1990 and the population was 
initially suspicious, leading to selective participation in the study. The sick, some of 
whom could have been HIV positive, were less likely to participate at first because of 
their fear that serological surveys were aimed at identifying HIV infected individuals 
and injecting them with a lethal chemical. Secondly, the amount of blood drawn was 
thought to be substantial and many sick individuals declined to consent to bleeding in 
the initial survey. However as the MRC survey established strong community 
mobilization and networks, and employed local staff from the study villages these fears 
diminished and more people participated, many of whom had never had a previous HIV 
test. 
Thus, despite the apparent increase in HIV prevalence from 1989 to 1993, it is possible 
that when HIV surveillance started in 1989 in this popUlation prevalence of HIV had 
already started declining. 
2.5.3. Declining HIV prevalence up to 2000 
What caused the decline in HIV prevalence in Uganda from the early 1990's to 2000? 
There are several factors that could have contributed to this decline. In many epidemics, 
it is possible for disease incidence to peak because the most susceptible people get 
infected first and then to fall because of the depletion of susceptible subjects (the natural 
course of the epidemic). This is followed by a fall in prevalence. In Uganda, estimation 
of HIV incidence through modelling has indicated a peak in incidence in the mid-1980s, 
followed by a rapid reduction in the later 1980s but no further substantial reduction 
through the 1990's(57). In the MRC cohort, the number of new HIV infections over the 
10-year period 1989-1999 was approximately 190, with an overall average annual 
reduction in incidence of about 0.45 per 1000 person years of observation. Though 
small, this reduction in incidence could have made some contribution to the decline in 
prevalence among males up to 2000. 
Migration and mortality are some of the underlying determinants in the proximate-
determinants framework that could explain these trends. As shown in figure 2.8, the 
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decline in prevalence for all ages particularly in the mid-1990s was a result of a net 
outflow of HIV positive migrants and more deaths of HIV positive individuals. The 
greatest decline in prevalence was observed in young people aged 20-24 years, though 
this cannot be explained by mortality alone. HIV infected individuals in this age group 
would have recently acquired HIV infection with a low mortality rate during the study 
period. Out-migration would have to be higher in HIV positive than HIV negative 
individuals to reduce HIV prevalence in this age group though this is plausible since 
"mobile" individuals are more likely to acquire HIV. There seems to have been very 
little change in incident cases during the years when prevalence decline was most 
evident. 
Changes in sexual behaviour patterns (abstinence, age at first sex, number of sexual 
partners and condom use) are proximate determinants that could also offer possible 
explanations for the decline in HIV prevalence. It has been suggested that Uganda's 
success story was a result of the reduction in sexual risk behaviour, the evidence for 
which I have presented in this chapter. For example, we observed an increase in both 
primary and secondary abstinence among teenage boys and girls. Between 1992 and 
1997, the median age at first sex among teenagers increased (p=0.002) among males, 
but there was no change in females. The age-specific prevalence of being married 
decreased among females aged 16-19 years but there was no change in males. Ever use 
of condoms (for all ages) increased significantly between 1992 and 1997 among males 
but there was no change among females. We also observed a decrease in condom use at 
last sex with a casual partner among married people, though we did not observe clear 
trends in the number of sexual partners. 
These reductions in risky sexual behaviour were a consequence of political support and 
openness about HIV in the late 1980s, the establishment in 1987 of the first ever 
national AIDS Control Programme (ACP) followed in 1992 by the multi-sectoral 
Uganda AIDS Commission in 1992, and the strong HIV prevention campaigns delivered 
by these organisations. The ACP introduced new policies, expanded partnerships, 
promoted public health education for behaviour change, strengthened sexually 
transmitted disease management, improved blood transfusion services, as well as care 
and support services for persons with HIV/AIDS(58). The ACP model of community 
mobilization and communication enabled HIV campaigns to reach the general 
population and target groups of all ages in both rural and urban areas. Equally important 
was the recognition and respect of those already infected with HIV. This was mainly 
through the creation of various indigenous care and support organizations for HIV 
positive individuals particularly The AIDS Support Organisation. These organizations 
and key individuals have played an important role in advocating against stigma and 
discrimination. The establishment of voluntary counselling and testing (VCT) centres 
such as the AIDS Information Centre together with openness around HIV provided 
encouragement for the general public to access VCT. The impact this alone could have 
played in reducing HIV prevalence is hard to estimate. However, combined with other 
interventions such as improved diagnosis of, and treatment of sexually transmitted 
infections, it must have contributed to the observed decline. Unlike other African 
countries this high level of political support and muti-sectoral approach appears to have 
been special to Uganda. 
2.5.4. Increasing HIVprevalencefrom 2000 
Why was the declining trend in HIV prevalence up to 2000 not maintained? There are 
several explanations that could be considered; underlying and as well as proximate 
determinants will be considered. 
Firstly, were there major changes in the population structure such as the migration of 
HIV positive and high risk people into the MRC study area at about the time prevalence 
began to increase? Similar epidemiological trends have been observed across the 
country, supported by data from national sentinel surveillance and these observations 
were not unique to this cohort alone(lJ). Moreover, during the 2000s, there were no 
changes in the proportions of HIV positives among in and out migrants to the study area 
(figure 2.8). and overall no net in-flow of migrants. The main mode of transmission has 
remained predominantly heterosexual and there have been no reported changes in HIV 
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transmission patterns in sub Saharan Africa(59) to explain the decline in HIV 
prevalence. 
Were there methodological changes over time in the MRC study? The data collection 
methods have remained unchanged over time with the same field survey team, some of 
whom have been following the cohort since the first survey in 1989. Similar laboratory 
testing algorithms using two different EIA systems (Recombigen HIV -I EIA and 
Wellcozyme HIV-I Recombinant) have been maintained throughout the study period. 
Similarly the survey coverage rate has been approximately 70% annually. Therefore 
there have been no differences in data quality to suggest any methodological biases that 
could explain the changes in HIV trends. 
Could the HIV molecular epidemiology in this cohort have changed in recent years to 
explain the reversal in the epidemiological trends? Data on HIV subtypes in this 
population reveals that subtypes A and D are the most prevalent with a few recombinant 
viruses. No significant changes in the subtypes of HIV infection in the cohort have been 
observed in this cohort(60). 
What has been the effect of introducing antiretroviral therapy (ART) in this cohort? 
There is evidence that ART reduces viral load both in blood and genital secretions(61-
62). This potentially decreases infectiousness and incidence(63) but also leads to a 
reduction in mortality which would increase prevalence over time. ART was introduced 
in the MRC cohort to those with CD4 < 250 cells/mm3 in 2004, according to the 
Ministry of Health ART guidelines, and by the end of 2008 about 200 patients had 
started treatment. Consequently the introduction of ART could potentially have 
contributed to the rise in prevalence from the mid 2000s because of improved survival. 
Indeed there was an observed reduction in number of deaths in the later years of the 
2000s (figure 2.8). 
Patterns of sexual behaviour from 2000 onwards among older adults (25-44 years) are 
inconsistent(55) and cannot fully explain the increase in HIV prevalence. For example, 
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condom use at last sex act with any partner decreased in men from 18.9% in 1996 to 
15.3% in 2000 and 14.7% in 2003, and then increased to 15.6% in 2005 and 18.1% in 
2006 (p for trend <0.001). Among women the rates were 5.7% in 1996 increasing to 
8.6% in 2000, then a decrease to 8.0% in 2003 and 7.6% in 2005, followed by an 
increase to 9.9% in 2006 (p for trend 0.71). 
Though the sexual risk behaviour changes from mid 2000 have not been well 
demonstrated there is evidence that people's perceptions regarding HIV/AIDS and 
sexual behaviour are changing for various reasons. Risky sexual behaviour among 1I1V-
infected people has been shown to rise in this cohort with some indications that ART 
availability may also increase risky sexual behaviour among HIV -un infected 
individuals(64). It is possible that the initial fear of AIDS related to the deaths of close 
relatives and friends during the early years of the epidemic may have declined after 
more than two decades. On the other hand, the inconsistent trends in sexual behaviour 
from 2000 onwards suggest that the relationship between the availability of ART, 
changing attitudes towards HIV and sexual behaviour is not straightforward. 
There has also been more emphasis within various 1IIV/AIDS programmes towards 
treatment and a shift from the strong HIV prevention strategies of the early 1990s 
together with less funding for HIV prevention. It is believed that the strong political 
support for the ABC strategy in the early years of the epidemic changed in the early to 
mid 2000s. There was a shift within the ABC strategy towards US-based abstinence-
only initiatives and less comprehensive sex education and condom promotion. These 
factors could partially explain the observed rise in prevalence trends, although trends in 
sexual behaviour after 2000 are less clear than those before 2000. 
HIV transmission in stable relationships is another factor that could have driven the 
epidemic among older people in whom rate of condom use is very low. The HIV 
discordance rate among married couples in Uganda is estimated to be about 5-7%(65). 
The 2004-2005 Uganda National Sero-Behavioural Survey showed that among couples 
where at least one partner is HIV positive, 40% are HIV discordant and only 9% are 
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aware of the HIV status of their spouse(66). There is also evidence, where there has 
been individual testing within couples, that disclosure of HIV status is either delayed for 
several years or never occurs for various reasons including blame and fear of domestic 
violence and marital disruption(67). 
Summary of explanations for observed trends in HIV prevalence in the 1990s 
Underlying determinants Direction of trend 
Marital status decrease In age-specific prevalence of being married 
(women) 
Migration net outflow of HIV positive individuals 
Mortality increase among HIV positive individuals 
Proximate determinants 
Age at first sex 
No. of sexual partners 
Condom use 
Condom use 
increase in primary and secondary abstinence (teenagers) 
no clear trends 
ever use increased (all ages in males) 
at last sex with casual partner increased (women) 
In summary, the increase in HIV prevalence since 2000 is not fully understood. 
However, improved survival due to ART, changes in sexual behaviour, and a shift in 
government efforts in HIV prevention towards care and treatment may have played 
some role, but it is difficult to establish their relative contribution. There were no 
changes of in and out migration among HIV positives during this period. 
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2.6 Limitations of using data from population cohorts to 
examine trends in HIV infection. 
Although population cohorts such as the MRC cohort provide a unique opportunity to 
examine data on trends in HIV infection, they are susceptible to limitations that could 
limit their validity and generalisability to other populations. Firstly, there is a tendency 
for the participants to modify their behaviour as a result of being followed in such 
longitudinal studies even in the absence of any active intervention other than provision 
of testing and counselling, and HIV education (Hawthorne effects). Secondly, the dates 
of seroconversion for HIV incident cases were estimated to be the mid-point between 
the date of the last negative test and the first positive test. For an individual who 
participated in one survey round and was HIV negative but subsequently participated 
after three survey rounds and was found to be HIV positive, the midpoint would not 
necessarily reflect the actual year of seroconversion. The actual date could have been 
anywhere between the two survey rounds in which such an individual participated, in 
this case over 4 years. Thirdly, our general population cohort was carried out in one 
small part of Uganda, one of those that were first affected by the HlY epidemic, and it is 
not possible based on data from the cohort alone to determine how generalisable the 
findings are to other parts of the country. Finally, despite the large size of the cohort, the 
annual number of HIV incident cases was not sufficient to provide precise estimates of 
incidence or of trends in incidence, and consequently difficult to interpret. One potential 
way of addressing this limitation is the use of alternative statistical methods such as 
moving averages which smooth the data and which may provide a clearer picture of 
trends in HIV incidence. Such an approach could be explored in future analyses. 
2.7. Explaining age and sex differences in HIV prevalence 
2.7.1. Sex differences in HIV prevalence 
The observed sex-differences in HIV prevalence are similar to those that have been 
observed in other sub Saharan African countries with women having higher rates than 
men. Several explanations have been suggested for these sex differences. Age at first 
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sex in girls is much younger than in boys, and often girls tend to have sex with older 
men who are likely to provide better economic support but are more likely to be HIV 
positive. Kelly and colleagues have demonstrated that the age difference between 
young women and their male partners is a significant HIV risk factor, and that this could 
partly explain the high HIV prevalence in young women(68). Similarly age differences 
between female and male sexual partners were found to be a major behavioural 
determinant for the more rapid rise in HIV prevalence in young women than in men in 
Manicaland( 69). 
In addition, there is evidence that male-to-female HIV transmission is more efficient 
than from female-to-male(65, 70). There are several biological factors that make women 
more susceptible to HlV than men: in the young age group the transition of the mucous 
membrane in young girls from a thin single layer of cells to a thick multi-layer wall is 
often not completed until the late teens or early twenties. The "immature" genital tract 
surface is thus less efficient as a barrier to HIV(71). The mucus of the female genital 
tract that acts as a physical barrier may also be less efficient in the presence of sexually 
transmitted infections. Asymptomatic and untreated STI, such as gonococcal and 
chlamydial infections among women are more prevalent than in men and contribute to 
their increased susceptibility to HIV. HSV-2 infection rates in women are much higher 
than in men and this also contributes to higher HIV prevalence(l7). While we did not 
collect data on intravaginal practices such as "dry sex" and vaginal cleansing in this 
population, there is data indicating that this is common in different populations in sub-
Saharan Africa(72) and could be other possible risk factors that may increase women's 
susceptibility to HlV infection. Bacterial vaginosis has also been shown to be 
associated with increased HIV acquisition(73). Women are also less likely than men to 
negotiate safer sex practices such as use ofcondoms(74-75). 
The decline in HIV prevalence among 20-24 year old men appears to have stopped 
approximately three to four years earlier than in women of the same age group. The 
reasons for the decline in prevalence stopping earlier in young men than women may be 
related to the transformation of the rural study area in the mid 1990s. This area, that was 
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quite rural in the early years of the study turned into a "semi urban" area with more 
transport connecting neighbouring towns and the district capital along the trans-African 
highway and electrification of the trading centre in the study area. Rural men started to 
trade with the neighbouring towns that had much higher HIV prevalence than the rural 
communities. Often men travelled and occasionally stayed away from home for a few 
days. With a little more income at their disposal, this could have put them at higher 
HIV risk through sexual mixing in the urban setting with higher prevalence among 
women available for sex. However this "urbanization" effect on HIV prevalence could 
have taken a few more years to change prevalence trends in women. This lag could have 
been due low transmission potential of HIV from the men to their rural partners, since 
on average transmission will occur after many sex acts. 
2.7.2. Age differences in HIV prevalence 
Differences in sexual behaviour and the uptake of HIV prevention among different age 
groups could partly explain age differences in HIV prevalence. In the early years of the 
epidemic peak incidence was estimated to occur among 13-24 year 01ds(76) and HIV 
prevention control often targeted young adults and those who were unmarried. Less 
focus was put on people who were ever married and those aged above 30 years. In 
addition young adults are more likely to use condoms than older people(77), which 
could have contributed to the decline in prevalence among young age groups. The 
increase in HIV prevalence among those aged 35 years and above may be a consequence 
of delayed and slower sexual behavioural change in older persons, who are less likely to 
change their behaviour and are less amenable to safer sex interventions than younger 
age groups. 
Another possible epidemiological reason is that different cohorts of individuals pass 
through different age-bands. For example the rise in HIV prevalence seen among the 
35+ year age group in 2000s could be due to an earlier high prevalence among the 25-34 
year olds in the 1990s. Similarly the decline among the 20-24 year olds in the 2000s 
could be partly a reflection of low incidence and prevalence among the 13-19 year olds 
in the 1990s. 
69 
2.S. Comparison with other countries in Africa 
What have been the trends in HIV prevalence and incidence in other East and Southern 
African countries? The decline in HIV prevalence in the Uganda MRC cohort between 
1990 and 2000 and indeed in other parts of the country occurred in a population that 
received health education through national programmes. There are a number of other 
African countries that also initiated national HIV health campaigns including Zimbabwe 
and Kenya. These are two countries where HIV prevalence has also declined. 
2.8.1. Zimbabwe 
In Zimbabwe data from the antenatal clinics (ANC), prevention of mother-to-child 
transmission (PMTCT) and VCT programmes, the ZVIT AMBO clinical trial (a large 
vitamin study) and the Manicaland studies (from rural Zimbabwe) all indicated that 
there was a decline in HIV prevalence from 2000 to 2004 in both urban and rural 
populations. According to ANC data, HIV prevalence declined from 32.1 % in 2000 to 
23.9% in 2004 (p<0.001)(78). Similarly data from the ZVITAMBO study that enrolled 
pregnant and post-natal women in Harare indicated that HIV prevalence declined 
steadily from 36% in 1996 to approximately 21 % by mid 2004. The Manicaland rural 
population household survey also observed a decline in prevalence among women aged 
15 to 44 years from 25.9% to 22.3% (p=O.015). There was a corresponding decline 
among men between the ages of 15 and 44 years old, from 19.5% to 18.2% (p=O.OI), 
with declines in all age groups except men over 35 years. Though the declining trends in 
the Manicaland study were significant they were much weaker (14% in women and only 
a 7% reduction in men) than the trends seen in Uganda between 1989 and 2000. A more 
recent analysis of all published and unpublished data available on trends in HIV 
prevalence, incidence and mortality has indicated evidence of a decline in prevalence 
from the late 1990s up to 2006, a rise in mortality in the 1990s that levelled off after 
2000, reductions in risky sexual behaviour and a fall in HIV incidence(79). 
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2.8.2. Kenya 
In Kenya the epidemic trends have been monitored through annual sentinel surveillance 
in ANCs since 1990 and sexual behaviour through the national DHS in 1989, 1993, 
1998 and 2003(80). There were strong indications from the surveillance data that HIV 
prevalence started declining around 1998 in some of the sentinel sites and in other sites 
from 2000. Mean HIV prevalence in five sites declined from 25.1% in 1998 to 7.9% in 
2004 (69% decline). A decline in other sites started later, prevalence falling from 14.7% 
in 2001 to 4.3% in 2003. 
2.8.3. Explanations for trends in HIV prevalence in Kenya and Zimbabwe 
A decline in HIV prevalence was seen in both Zimbabwe and Kenya over time. A 
review of data from Zimbabwe to explain the HIV decline indicated that behavioural 
changes, mainly reductions in extramarital, commercial and casual sex, made the 
greatest contribution. These were thought to be as a result of increased awareness due to 
AIDS associated mortality and economic decline resulting in less disposable income 
amongst men, in addition to HIV prevention programmes(SI). In Zimbabwe sexual 
behaviour data have indicated trends towards less risky behaviour which explain the 
decline in HIV prevalence. For example in the eastern part of the country a delay in 
sexual debut among teenage boys and girls and decline in reported casual sex among 
sexually active men and women were noted. There was also a reported increase in 
consistent condom use with recent casual partners(82). Similar findings were observed 
using data from other surveys in the country such as the Young Adult Survey and the 
Population Services International survey that indicated reductions (though not 
statistically significant) in sexual experience among those aged 15-19 years between 
2001 and 2003, and a significant decline in reported casual partners in the past 12 
months(78). Similarly trends in HIV prevalence in Kenya reflected changes in sexual 
behaviour observed in the DHS which included a rise in age at first sex, an increase in 
condom use and a decrease in the proportion of adults with multiple sexual partners in 
the last 12 months(80). 
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Though there was a decline in HIV prevalence in both countries there are some 
differences from Uganda. First, the decline in Zimbabwe and Kenya occurred much later 
than in Uganda and secondly the decline was smaller than in Uganda. An older HIV 
epidemic in Uganda is one factor that could explain the timing of the decline in HIV 
prevalence. The first HIV/AIDS cases were identified in Uganda in 1982, compared 
with late 1987 in Kenya and the mid 1980s in Zimbabwe. Modelling work in Uganda 
indicates that HIV incidence peaked in 1987 or shortly thereafter and declined rapidly to 
about 1993 suggesting that behavioural changes had taken place by 1987 and continued 
at least through to 1993. In Zimbabwe HIV incidence is estimated to have peaked 
between 1988 and 1990 in the capital Harare, with the peak in other parts of the country 
occurring several years later(83). The peak incidence in Kenya is not well documented 
though it could have occurred around 1993(84). 
One of the significant factors that could have contributed to the decline in HIV 
prevalence and changes in sexual behaviour in all countries was the government 
developing AIDS policies and establishing National AIDS Control Programmes. In both 
Kenya and Zimbabwe these were established in 1987 at about the same time as in 
Uganda. 
The high-level political support accorded to the national HIV prevention efforts in 
Uganda early in the epidemic was not evident in Kenya until the late 1990s. There was 
political denial of the existence of HIV in Kenya for much of the 1980s and 1990s. 
Similarly the political and economic climate in Zimbabwe in the 1990s did not offer 
support to the prevention efforts and this could have delayed the decline in HlV 
prevalence. 
We have seen a recent increase in HIV prevalence in Uganda but not in the other two 
countries. There are however data from the 2007 Kenya AIDS Indicator Survey 
conducted by CDC, World Health Organisation (WHO) and the Kenya Medical 
Research Institute indicating that HIV prevalence rose to 7.8% in 2007, a slight increase 
from the 6.7% prevalence recorded in 2003. No data on an increase in prevalence have 
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come from Zimbabwe. Whether the recent increase in HIV prevalence seen in Uganda 
will be observed in the other East and South African countries needs to be closely 
monitored. 
2.9. Conclusion 
Very little was known about HIV/AIDS in Uganda and in many other parts of sub 
Saharan Africa prior to the mid-1980s. Using data from the rural population cohort of 
the MRC Programme and from other sources in Uganda trends in HIV prevalence and 
incidence have been described. Overall, HIV prevalence declined in both men and 
women between 1990 and 2000 especially in those aged 20-24 years, but then increased 
from 2000 onwards. On the other hand, in those aged 35 years and above, a steady 
increase in HIV prevalence was observed in both females and males throughout the 
study period. I used a proximate determinants framework to better understand the trends 
in HIV prevalence. The decline in prevalence could have been due to the natural course 
of the epidemic but also due to underlying determinants (a net outflow of HIV positive 
migrants, more deaths of HIV positive individuals) as well as proximate determinants 
(reductions in risky sexual behaviour). Reasons for the increase in prevalence since 
2000 are not fully understood although a shift to more risky sexual behaviour and 
improved survival due to ART may have played a part. Trends in HIV incidence rates 
are less clear than prevalence trends. The decline in incidence seen from the early 1990s 
could be an indication that the decline could have started earlier, possibly in the late 
1980s. 
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Chapter 3. Interventions to prevent HIV transmission 
Summary 
In the early years of the HIV epidemic in Uganda, government efforts to control the 
epidemic were largely dependent on the ABC (Abstinence, Be faithful, Condom use) 
model, which led to behaviour change and a subsequent significant decline in infection 
rates. There was however still a need to develop and evaluate other prevention strategies 
to control the epidemic. A series of large clinical trials have been conducted in Uganda 
to evaluate potential HIV prevention strategies. Based on our knowledge of HIV 
transmission dynamics and associated risk factors, key interventions were designed and 
evaluated among established adult cohorts. The first intervention aimed to evaluate the 
impact of a behaviour change programme with or without improved management of 
sexually transmitted diseases (STDs) on HIV transmission. Subsequent interventions 
were based on an understanding that women are more vulnerable to HIV, and hence 
there was a need to evaluate female-controlled prevention methods (vaginal 
microbicides). Despite evidence that STDs are important cofactors in the transmission 
and acquisition of HIV infection and that risky sexual behaviour increases the risk of 
HIV, a well designed and implemented trial targeting these risk factors did not show any 
effect on HIV transmission. Similarly a large phase III vaginal microbicide trial that 
evaluated PRO 2000 vaginal microbicide gel that had shown promise in animal and in 
vitro studies did not prevent HIV transmission among sexually active women. Possible 
reasons for the lack of effect of these prevention strategies are examined. 
3.1. Introduction 
This chapter describes trials carried out to evaluate the impact of preventive 
interventions on HIV transmission in the MRC cohorts in Uganda and examines why the 
interventions showed no impact. The first six years of epidemiological and clinical HIV 
research in the MRC Uganda rural cohort provided an understanding of HIV 
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transmission dynamics. It was evident, as data in chapter two have shown, that HIV 
prevalence was high (8%) and that the epidemic was having a substantial demographic 
and socio-economic impact on the study population, reflecting what was happening in 
the whole country and possibly in many other parts of Africa. At that time the available 
prevention strategies were based on the Abstinence, Be faithful and Condom use (ABC) 
model. Briefly the details of the model are: Abstinence focuses mainly on young persons 
who have never had sex and urges them to delay starting sexual activity (primary 
abstinence). It also encourages secondary abstinence (returning to sexual abstinence 
after a period of sexual activity) among those adults not in permanent stable 
relationships. The 'Be faithful' component encourages individuals, after determination 
that none of the partners is HIV infected, to have one long-term or life-long sexual 
partner but also acknowledges polygamous relationships where this is within cultural 
and religious norms (,Zero grazing'). The Condom aspect aims to ensure consistent and 
correct condom use with non-regular sexual partners. To facilitate this concept there was 
a government commitment to ensure regular and sufficient supplies of condoms. 
Condom promotion and distribution was through government health facilities, high risk 
venues (e.g. bars and hotels), but also through social marketing. A number of 
approaches were used to deliver these messages such as newspapers and youth-targeted 
radio programmes. While there is evidence that these interventions had some impact on 
HIV transmission, the prevalence and incidence of infection continued at a high level, 
and it was important to design and evaluate new preventive interventions that could 
potentially achieve substantial reductions in HIV incidence. 
This chapter describes two large trials conducted in Uganda. The Masaka 
STD/behavioural intervention trial (1994-2000) and the vaginal microbicide phase III 
trial (2005-2008) under the Microbicides Development Programme (MDP), were both 
conducted in rural Masaka district. The STD/behavioural study was a three-arm 
community randomized controlled trial of 18 rural communities (approximately 94,000 
adults). Impact assessment was on a subset of approximately 14,500 adults. The MOP 
trial was a multicentre randomized double-blind study conducted in 4 African countries 
among sexually active HIV negative women. The trial enrolled 9385 women, 850 of 
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whom were recruited in Uganda. The main outcome measure in both studies was 
incidence of HIV infection. 
3.2. STD/behavioural interventions 
The predominant mode of HIV transmission among adults in sub Saharan Africa is 
heterosexual transmission. This is influenced by many factors including sexual 
behaviour and biological determinants such as the presence of sexually transmitted 
infections(85-86). Promotion of safer sexual behaviour and control of STDs were 
therefore important potential strategies to prevent HIV infection(87-88). The sexual 
behaviour change model used more innovative strategies and went beyond what was 
being provided through the national programmes. The national HIV campaign 
programme was formalised Information, Education and Communication (IEC) strategy. 
Prior to 1995 the strategy was through mass media (radio and print) and institutional 
communication, with virtually no personal communication about HlV/AIDS. The 
different organizations involved were largely faith-based, community-based, local and 
international non-governmental organizations in addition to government institutions. 
There were however some limitations to this strategy - radio and print media might not 
have been able to reach sufficient proportions of the population especially in rural areas 
due to poor coverage, timing of the broadcasts and illiteracy. Also, the institutions were 
likely to disseminate some but not the entire IEC package. For example the faith-based 
organizations were more likely to disseminate information on abstinence and 
faithfulness but not information on condoms. There were also limitations in government 
health facilities: few staff running already very busy clinics and not able to offer quality 
STD care, health education, counselling and testing, and with an irregular supply of 
condoms and STD drugs. 
No randomized controlled trials had been conducted in sub-Saharan Africa to assess the 
impact of these prevention strategies prior to the Mwanza (Tanzania) sexually 
transmitted diseases (STD) intervention trial, which was conducted between 1991 and 
1995. The trial targeted treatment of symptomatic STD patients using syndromic 
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management(28). This trial was followed by the Rakai trial of STO mass treatment of 
the general population (1994-1998) in Uganda(29). In contrast with trials of STO 
treatment, no randomized trial of sexual behaviour interventions using HIV incidence as 
an outcome measure had been reported from Africa(89-90), even though governments 
and agencies spent a great deal of money and resources on health promotion and 
education programmes to change sexual behaviour. 
The rationale of STO management as an HIV prevention method is based on STO 
cofactor effects on sexual HIV transmission indicating at least a two to five fold 
increased risk for HIV infection among persons who have other STOs, including genital 
ulcer disease and non-ulcerative, inflammatory STOs(31, 9\). STOs facilitate HIV 
infectiousness and susceptibility through various biological mechanisms: inflammatory 
STOs such as gonococcal and chlamydial infections have been shown to increase 1IIV 
shedding and HIV viral load in genital secretions(92-93). In genital ulcerative diseases 
there is disruption of the epithelial and mucosal barriers which leads to increased 
susceptibility to HIV infection. In addition there is increased HIV shedding in the 
genital lesions among patients with genital ulcer disease. Correct diagnosis and early 
STO treatment is thus a potential HIV prevention strategy. The aim of the intervention 
was to reduce the prevalence of STOs in the popUlation and thus to reduce the role of 
STOs in HIV transmission. 
To better understand the contribution of behaviour change and improved STO 
management interventions to HIV prevention, a community randomized trial was 
designed and conducted in rural Masaka district. south west Uganda between 1994-
2000. The hypothesis was that unsafe sexual behaviour and acquisition of an STO were 
independent risk factors for HIV infection(94). The trial aimed to assess the impact of 
an IEC package alone and in combination with STO management at primary health care 
level. and to determine the impact of each approach on HIV incidence and other 
STOs(21-22). The trial consisted of three arms with six communities in each arm. Six 
communities were allocated to receive behavioural interventions alone (group A), six 
communities allocated to behavioural and STO interventions (group B). and six 
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communities to routine government health services and community development 
activities (group C). The elements of randomization were communities (each with 10-12 
vi llages) that had government health faci li ties. The 18 trial communities were se lected 
and grouped according to defined characteristics: type of road pass ing through (a major 
road, secondary road or no secondary road); distance from the district capita l « 20 km, 
20-40km, >40km); and quality of health facility and level of staffing (low, medium, 
high). To minimize contamination, the communities within each triplet as we ll as 
between triplets were as geographically di stant as poss ible (figure 3.1). 
Figure 3.1 Masaka Trial study communities 
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3.2.1 Intervention activities 
The IEC component of the study consisted of community-based and school-based 
programmes, which were conducted in two of the three study arms, in a total of 12 
communities (arms A and B). The IEC package was based on the Behavioural Change 
for Interventions model (BCI) which focuses on knowledge acquisition, skills 
development, motivational support and attitudes development. The aim was to give 
correct knowledge, to correct misconceptions about HIY and other STDs, and to 
promote safer sexual behaviour and practices. The community-based intervention was 
implemented using locally accepted community approaches such as drama groups with 
particular attention to development of peer-based education systems including 
establishing AIDS prevention committees, community educators and a parish 
coordinator in each community. The interventions were implemented using various 
channels that included small and large community meetings, drama, video shows 
focusing on specific HlV messages, and distribution of information leaflets and one-one 
discussions. The central lEC staff (coordinator, health educators, condom distributor) 
oversaw the community-based activities through training and supervision of field based 
groups whose main tasks included providing information and advice about HIY/AIDS 
and STDs. They also carried out condom promotion and distribution. A total of 540 field 
based workers implemented the activities. 
The community-based IEC channels were carefully chosen so as to be relevant to the 
target population. For example, drama shows are a familiar and acceptable channel to 
communicate a story in such settings. Five plays were written in the local language by a 
consultant and covered important messages: the role of sugar daddies, extra marital sex, 
the role of peer pressure among youths especially girls, and community resistance to 
condoms. The video shows were an innovation that excited and attracted large 
audiences and showed the local plays in addition to covering other topics: disbelief 
about AIDS and subsequent sex with AIDS widows, counselling and testing, sex and 
consequences among school youths. The intervention was adequately delivered with an 
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average of six attendances of IEC activities (video shows, drama shows, health 
education by field-based community educators) per adult target(95). 
The school-based programme was a 19-activity extracurricular school-based 
comprehensive AIDS education programme that targeted students in the top two years 
of primary school and the lower two years of secondary school in schools from the lEC 
communities. A senior woman teacher and a science teacher in each school were 
identified and requested to take part in a series of three training workshops prior to 
embarking on implementation in their various schools, and within the school's normal 
timetable at the teachers' discretion. They would either be incorporated into existing 
lessons or taught during out-of-school hours. 
The school-based programme was initiated by the trial team as AIDS education in 
Uganda was quite limited in both content and coverage. The programme was adapted 
from the WHOIUNESCO' School Health Education to prevent AIDS and STD- A 
Resource Package for Curriculum Partners(96). Though this was a comprehensive 
teacher-based intervention that focussed on basic HIV/AIDS information, role-play 
activities, condoms and safe sex negotiation, there were some limitations of the 
programme. We purposely left the implementation of the programme to the discretion of 
the teachers either to be incorporated into existing lessons or taught during out of school 
periods, which could potentially impact on its quality. We were also aware that there 
could be resistance to condom discussion in schools either from the teachers themselves 
or from the wider community including parents. The trial team made support visits to 
the schools that aimed to discuss with teachers any difficulties with the intervention 
rather than supervise how they were actually delivering the activities in classrooms. We 
utilised both qualitative and quantitative techniques to evaluate the programme. In 
summary, we noted that the programme was incompletely implemented and some topics 
such as condoms and role-play activities were hardly covered. 
The STD intervention targeted the six communities in arm B (approximately 32 000 
adults) and involved the participation of both government and private health units. The 
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aim was to improve STD management by focusing on the quality of care and followed 
the syndromic management approach(97}. STD syndromic management, recommended 
by WHO, is a cost-effective strategy based on treatment of patients with defined clinical 
syndromes for the major aetiologies shown to be responsible for these syndromes in the 
local population. This approach is appropriate in developing countries with limited 
laboratory infrastructure as it avoids the need for patients to be tested for specific 
aetiologies at the point of care. Health workers from all units were trained on correct 
syndromic diagnosis and treatment, counselling and future risk reduction, condom use, 
follow up visits while on treatment, partner notification, and record keeping. Regular 
supervision by trial central staff was carried out every 2 weeks. All units were supplied 
with basic equipment and supplies including condoms and essential drugs to facilitate 
improved STD management. We ensured that health units had sufficient stocks of 
essential drugs and supplies at all times. 
3.2.2. Comparison arm activities 
Activities in the comparison arm (arm C) focused on improving community 
development and general health-related issues important to and chosen by communities. 
Three main areas were identified in consultation with the community. Firstly, support 
and training to existing profit making and self-support groups and clubs, in management 
skills and appropriate technology to generate income and become self-sustaining. 
Secondly, a home-based care programme to treat elderly and bedridden clients. Thirdly, 
health promotion targeting important topics such as malaria, breast feeding practices, 
family planning, sanitation and diarrhoeal diseases. 
All study arms were provided with social marketing of condoms and voluntary HIV 
counselling and testing. 
3.2.3. Impact evaluation and ｡ｮ｡ｬｹｳｩＮｾ＠
Impact assessment of the interventions was through three Knowledge, Attitude, 
Behaviour, Practice (KABP) and serological surveys, conducted at 18-24 month 
intervals, in a sample of 750-1000 adults (13+ years) in each community. The sample 
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was obtained by surveying 3-5 villages closest to the health unit. The primary outcome 
was HIV incidence. Secondary outcomes were incidence of herpes simplex virus type 2 
(HSV2) infection and active syphilis and prevalence of gonorrhoea, chlamydia, reported 
genital ulcers, reported genital discharge, and markers of behavioural change. Analyses 
were performed separately comparing arms A vs C and B vs C, taking account of the 
matching of communities, and potential confounders including baseline HIV prevalence. 
3.2.4. Summary of results 
Baseline results: Overall the baseline enrolment was high (72% of eligible population). 
Despite grouping and matching study communities based on HIV -related community 
characteristics (type of main roads, distance from the district capital, the quality of 
health facilities and level of staffing), HIV baseline prevalence varied by study 
communities (range = 4.2-20.3%) and also between arms; 8.8% in arm A, 10.1 % in arm 
Band 10.4% in arm C. There was however fair baseline comparability between study 
arms for potential confounders for HIV and STD infections except religion and history 
of genital ulcers which varied substantially. Reported rates of ever use of condoms, use 
with last casual partner, and proportion reporting two or more sexual partners in the past 
year were similar in all arms. The prevalence rates of STDs (syphilis, HSV -2, 
gonorrhoea and chlamydia) were also fairly similar across study arms. All analyses were 
adjusted for age, sex, and community-level baseline prevalence of the outcome (1I1V, 
HSV2, syphilis, reported genital ulcers, reported genital discharge). 
Intervention impact results: The proportions of eligible individuals providing a blood 
sample were 72% in the baseline survey, 72% in the round 2 survey and 91% in the 
round 3 survey. The median follow up of communities was 3.8 years (range 3.2-5.0). A 
total of 304 HIV events occurred over 41,060 person years at risk, with overall 
unadjusted incidence rate of 0.74 per 100 person years at risk. Highest incidence was 
observed in communities with highest baseline prevalence. Incidence of HlV did not 
differ between groups A and C or between groups Band C, even after adjustment for 
age, sex, and baseline HIV prevalence (table 3.1), or after additional adjustment for 
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genital ulcer disease and religion (group A vs C, incidence rate ratio 0·94 [95% CI 0·60-
1·45], p=O'72; group B vs C 1·00 [0'63-1'58], p=0·98). 
Impact on STDs was observed on HSV -2 incidence - lower in group A (behavioural 
intervention alone) than in group C (comparison ann) with an incidence rate ratio of 
0.65 (95% CI 0.43-0.97). This effect remained significant after additional adjustment for 
religion and genital ulcer disease. However there was no effect in group B (the same 
behavioural intervention plus STD intervention). There was an impact on active syphilis 
(high RPR titre) and prevalence of gonorrhoea in group B compared to group C (active 
syphilis incidence rate ratio, 0.52 [0.27-0.98]; gonorrhoea prevalence ratio, 0.25 [0.10-
0.64]). 
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Table 3.1 HIV prevalence, incidence and incidence rate ratios by triplet and arm 
Triplet Baseline HIV incidence/lOO pyar 
Prevalence (number of events/pyar) 
(0;') 
Trial Arm Trial Arm 
A B C A B C 
1 10 9 7 0.5 0.8 0.3 
(14/2716) (1912529) (912625) 
2 10 II 9 1.2 0.5 0.6 
(20/1627) (12/2336) (16/2596) 
3 II 17 12 0.8 1.7 1.2 
(1812382) (31/1819) (23/1888) 
4 4 8 7 0.4 0.5 0.5 
(6/1681) (11/2276 (15/2943) 
5 5 9 8 0.3 0.4 0.9 
(912768) (8/1975) (2112359) 
6 II 8 20 0.6 1.1 1.7 
(14/2173) (29/2701) (29/1670) 
Overall 9 10 to 0.61 0.81 0.80 
(81/13346) (110/13634) (113/14080) 
p-value is for paired t-test; 
* Adjusted for age, sex, baseline HIV prevalence. 
pyar: person years at risk 
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Incidence Rate Ratios (95%» CI) I 
AvsC BvsC 
Unadjusted Adjusted * Unadjusted Adjusted 
• 
1.50 0.96 2.19 2.01 
1.99 1.40 0.83 0.62 
0.62 0.71 1.40 0.98 
0.70 0.97 0.95 0.87 
0.37 0.51 0.46 0.54 
i 
0.37 1.29 0.62 0.97 I 
0.75 0.92 0.94 0.91 
I (0.36-1.57) (0.62-1.37) (0.52-1. 70) (0.56-1.47) I 
p=O.36 p=O.61 p=0.70 p=O.41 
Table 3.2 HSV-2 and syphilis incidence and incidence rate ratios, and gonorrhoea and chlamydia prevalence and 
prevalence ratios 
Trial Arm Rate Ratios (95% el) 
A B C AvsC 
HSV-2 incidence/tOO pyar (events/pyar)t Unadjusted Adjusted • 
2.3 3.6 3.5 0.66 0.65 
(100/4381.6) ( 167/4595.5) ( 16114628.6) (0.33-1.29) (0.43-0.97) 
p=0.17 p=O.040 
Active syphilis incidence/tOO ｰｾ＠ ar (any RPR titre) (events/pyar)t 
2.9 2.1 2.9 1.00 1.13 
(341/11866.5) (255112379.7) (366/12444.9) (0.61-1.64) (0.70-1.82) 
p=O.99 p=0.54 
Active syphilis incidence/tOO ｰｾ｡ｲ＠ (RPR titre ｾｴＺＸ＠ (events/pyar)t 
0.5 OJ 0.6 0.90 1.13 
(7211139.1 ) (43/1449.5) (83/1484.5) (0.44-1.86) (0.61-2.07) 
p=O.73 p=O.64 
f Gonorrboea prevalence (0/e)§ 
1.02 0.51 1.17 0.75 0.74 
(34/3339) (1813540) (4213589) (0.30-1.85) (0.30-1.82) 
p=O.45 p=O.43 
fCblamydia prevalence (%)§ 
1.35 1.92 1.81 0.59 0.59 
(45/3339) (68/3540) (65/3589) (0.20-1.72) (0.20-1.72) 
p_=O.26 ｾＮＲＶ＠
• Adjusted for Age and Sex. t Also adjusted for baseline HSV-2 prevalence. 
ｾａｬｳｯ＠ adjusted for baseline RPR prevalence. 
§ Pooled for R2 and R3 
Pyar - person years at risk 
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BvsC 
Unadjusted Adjusted * 
1.02 1.02 
(0.59-1.74) (0.69-1.50) 
p=0.94 p=0.90 
0.71 0.81 , 
, 
(0.52-0.99) (0.64-1.04) 
p=0.045 p=0.080 I 
0.53 0.58 
(0.33-0.84) (0.35-0.96) 
p=O.016 p=0.039 
0.29 0.28 
(0.12-0.71) (0.11-0.70) 
p=0.016 p=0.016 
0.99 0.99 I 
(0.70-1.41 ) (0.71-1.39) ! 
ｾ］ｏＮＹＴ＠ p=0.97 
3.3. Why was there no reduction in HIV incidence in the 
STD/behavioural trial? 
It is surprising that the interventions did not have an effect on HIV incidence, despite 
good evidence that HIV is transmitted through risky sexual behaviour and facilitated by 
the presence of STDs. Many HIV intervention trials conducted to date have shown 
negative results(98). In general, there are several reasons why interventions sometimes 
do not have the anticipated impact and some of these could have played a role in this 
trial. A recently proposed framework to discuss the negative results of randomized 
controlled trials of HIV prevention sets out the following potential explanations for such 
findings(98-99): (i) the concept is wrong; (ii) the concept is right but the actual 
intervention is "inert" or insufficient to demonstrate impact; and finally (iii) there were 
problems with the design or conduct of the trial. Following this framework, possible 
reasons for the findings in this trial are explored. 
3.3.1. The concept was wrong 
Prior studies in this rural district had indicated that STDs were highly prevalent, up to 
12% for syphilis and up to 36% in males and 72% in females for HSV-2(17, 100). 
Similarly, baseline STD prevalence and reported STD symptoms in the trial 
communities were high. Baseline data also indicated high risk sexual behaviour such as 
low condom use, high numbers of sex partners and casual sex in the last year. About 6% 
reported age at sexual debut below 13 years and approximately 40% between 16 and 19 
years(21). The MRC trial included a population where the predominant mode of 
transmission is heterosexual. The interventions that targeted sexual behaviour change 
and improved management of STDs were thus appropriate and had the potential to have 
an impact on HIV transmission. 
The IEC intervention used locally appropriate channels and was largely dependent on 
the IEC team who were residents within the communities throughout the entire trial 
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period with the aim of creating a sustainable and replicable lEe strategy. The school-
based component of the lEe was implemented as best as was practical given available 
resources although we have noted its limitations. The improved STD management was 
through syndromic management, a relatively simple approach to incorporate into the 
existing health care infrastructure. We focused on the factors that affect the quality of 
care in both government and private health units with regular support and supervision. 
Thus there is good evidence to suggest that the concept was right but the actual 
intervention could have been insufficient to demonstrate an impact at population level. 
3.3.2. Tlte concept is rigltt but tlte actual illterventioll is "inert" or insufficient to 
demonstrate impact 
The interventions were carefully designed and appropriate for the community and were 
of high quality(21). The behavioural intervention was largely delivered by 
approximately 560 field-based workers who had received very intensive training and 
were regularly supervised by central staff. There were high levels of behavioural 
intervention activity in the twelve communities with excellent coverage rates. For 
example, over the five year intervention period there were approximately 390,000 
individual attendances at over 80,000 lEe activities (community meetings, video shows, 
drama shows, and individual meetings with community educators), representing a mean 
of 6 attendances for each of the 64,000 target adults in the behavioural intervention 
communities with similar attendance rates for men and women. Approximately 58% of 
the attendances were among those aged 13-24 years and 42% among those aged above 
24 years. A total of 164,063 information leaflets were distributed. This is a mean of 2.6 
leaflets per target individual. Many leaflets would have been read by more than one 
individual. We also demonstrated that the messages were understood and retained by the 
participants(95, 101). Across all channels, many people were able to remember the main 
message three months or more after exposure. Individuals were most likely to remember 
the message from a community educator, followed by drama/video and then leaflets. 
Similarly the trial appeared to be acceptable to the community and in particular free HIV 
testing and counselling were very much appreciated. The field workers built their skills 
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and confidence and were well respected and accepted by their communities as providers 
of HIV / AIDS information( 1 02). 
On the other hand there was evidence that the school-based component of the IEC 
intervention was incompletely implemented due to insufficient classroom time and some 
topics such as condoms not sufficiently covered due to fear and sensitivity of the subject 
in such communities. These observations contrast with those observed in some other 
studies that have evaluated the impact of sex and HIV education programmes in schools. 
A review by Kirby and colleagues of 83 studies that measured the impact of curriculum-
based sex and HIV education programmes on sexual behaviour and mediating factors in 
a wide variety of countries, cultures, and groups of youth showed that the majority of 
studies found a significant positive impact on sex behaviours or outcomes(l03). An 
analysis of the curricula that had a positive impact identified 17 common characteristics 
that included their development, content and implementation. There are two possible 
reasons for our negative findings. First our programme was not adequately implemented 
because of insufficient classroom time to cover non-examinable topics, fear of 
discussing condoms that were not fully supported by parents and wider communities, 
and unfamiliarity with role-play techniques among teachers. Secondly, the programme 
was an adapted version of the WHO/UNESCO's school curriculum that had not been 
previously adapted, and may not have been appropriate for the target group in our 
settings. We also did not adequately assess the needs of our target group and 
consequently some of the activities were not consistent with the community 
expectations. It is therefore evident that our school-based programme did not fully 
comply with the Kirby characteristics. 
Interestingly the community development activities in the comparison group were also 
equally well accepted as the population regarded development as more important than 
AIDS education. STn treatment interventions were also adequately delivered in the six 
intervention communities. Over 12,000 STn cases (65% females) were seen at both the 
government and private health units; and approximately three-quarters of cases were in 
88 
those aged 20-39 years(2l). Therefore it does appear that the interventions were wel1 
delivered but were "inert" because they were applied at the wrong stage of the epidemic 
and in a population where STD rates and risk behaviour had already decreased. This was 
confirmed by the comparative analyses and modelling of the three STD trials discussed 
in section 3.3.4. 
A sub analysis examining outcome measures at an individual level was conducted 
comparing the arm that received the behavioural intervention alone, without improved 
STI management (arm A) and the comparison arm (arm e). Arm B was excluded as the 
effect of the behavioural intervention may be different in the presence of the STD 
intervention. This analysis differed from that of the main trial analyses that were 
performed at a community level(23). HIV incidence rates were lower in those who 
reported attending lEe activities in the past year compared to those who did not. This 
effect was significant in women who attended any activity (p=0.024) and in men who 
attended community meetings (p =0.045). This observed effect on IIlV was examined to 
see whether it was biased by non-attendance as a result of being away (a proxy for risky 
sexual behaviour). The effect was unchanged when adjusted further for confounding 
factors (age group, marital status, religion and travel outside the district). One limitation 
of this analysis could have been that measurement of lEe attendance and IIIV incidence 
was done in the same surveys (rounds 2 and 3), making it difficult to tease out whether 
HIV sero-conversion occurred before or after attending the lEe activity. However a 
similar effect was observed when we restricted analysis to attendance of IEC activities 
reported at round 2 and sero-conversion between rounds 2 and 3. Attendance of IEC 
activities was however not associated with a reduction in sexual behaviour (reported 
sexual partners and condom use). This could be due to reporting bias as in many other 
studies(1 04-1 05), relatively smal1 numbers of individuals engaged in high-risk sexual 
behaviour in the entire community so that it was difficult to detect any changes, or the 
methodology used (KABP questionnaire) which may not have been sufficiently accurate 
to measure sexual behaviour changes. This was an observational analysis and 
associations may have been due to confounding. For example, those accessing the 
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interventions may have differed from other community members, and may have been at 
lower risk of HI V even in the absence of the intervention. 
3.3.3. There were problems with the design or conduct of the trial 
The community development activities in the comparison arm, such as support to 
existing groups and clubs, home based care for the elderly and bedridden clients, and 
health promotion on non-HiV health problems are unlikely to have had an impact on the 
outcome measures (HIV incidence and STDs). It is however plausible that the presence 
of our own field staff from an HIV research organization, and social marketing of 
condoms and voluntary HIV counselling and testing as well as serological surveys (for 
which consent for HIV testing was first sought) could all have had some effect on the 
risk of HIV infection. If this is the case then this could potentially have diluted the true 
effect of the interventions. Did the intervention activities spill-over into the comparison 
communities? There was minimal spill over from the STD intervention communities to 
the comparison and the IEC arms. We regularly assessed the attendance in the STD 
registers within the six STD intervention communities. Overall only 1 % of all clinical 
visits in the STD registers within the STD communities were individuals from either the 
comparison or IEC-only communities, an indication that the majority of care was sought 
from health facilities within their own communities. There was however some spill over 
of IEC activities to the comparison arm - about 9% of individuals in the comparison arm 
reported attending at least one IEC activity, mainly attending a community meeting. 
Though some of this could be due to misreporting, for example reporting non-
intervention mobilization meetings for serological surveys, we noted some attendance 
from the comparison communities was a result of insufficient geographic separation of 
the intervention and comparison communities. 
The study might not have been adequately powered as the observed HIV incidence (0.6-
0.8%, table 3.1) was lower than had been initially assumed (a background annual 
incidence of 1.5%, at the time of the study design). 
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Finally, we believe that the timing of the trial could also have played a role in the 
negative result. The study was initiated in 1994 and completed in 2000. As discussed in 
chapter two, HIV prevalence rates started declining in 1993/94 and this continued to 
2000/01, with evidence of a decline in risky sexual behaviour in the late 1990's in a 
neighbouring study population in the same district. These declines occurred in the 
absence of any active intervention and were a reflection of what was probably 
happening in the rest of the country. This was consistent with the stage of the epidemic 
that was mature and generalised as has been observed in other settings with indications 
that reduction in risky sexual behaviour is a factor driving reduction in HIV 
incidence( 106). The spill-over to the comparison communities, the timing of the trial in 
relation to the stage of the epidemic in the country, and the lower HlV incidence than 
originally estimated suggest that the negative findings could have been partly due to 
problems with the study design, as well as deficiencies in the school based component 
of the IEC intervention. 
3.3.4. Comparison of trial results witlt Mwanza syndromic STD management trial 
and Rakai STD mass treatment 
The Masaka trial results in Uganda provided contrasting findings to the Mwanza 
syndromic STD intervention trial in Tanzania that had demonstrated an approximately 
40% reduction in HIV incidence (incidence RR 0.62, 95% Cl 0.45-0.85). The findings 
in the Masaka trial were however similar to those of the Rakai trial, also in Uganda, that 
evaluated the impact on HIV incidence of mass STD treatment at 10-monthly intervals 
and syndromic management at the time of the surveys (incidence RR 0.97, 95% CI 0.81-
1.61 ). 
In an attempt to explain these contrasting results from the three East African randomized 
trials targeting STDs to prevent HlV transmission, a collaborative modelling project 
using STDSIM, a stochastic simulation model of HlV and STD transmission, was 
conducted. The aim was to re-analyse and compare empirical data from the three trials 
and fit the STDSIM model to empirical data from each trial population, simulate 
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different interventions in each population and assess the relative effectiveness of 
different interventions in different populations. The main findings of this modelling 
project were that differences between the trial results could largely be explained by the 
differences between the three study populations(39, 107-108). Briefly, the demographic 
characteristics across the three trial populations were generally similar. The baseline 
HIV prevalence rates were however much higher in Uganda (16.5% in Rakai; 12.1% in 
Masaka) than in Mwanza (3.8%). The Ugandan epidemic was more mature than in 
Tanzania and was characterised by a reduction in risky sexual behaviour and lower rates 
of curable STOs at the time of the trials (Figure 3.2a and Figure 3.2b). This could have 
been due to the intensive national AIDS campaigns leading to high HIV awareness in 
Uganda, but also due to fear from the high mortality that had occurred in Masaka and 
Rakai in the 1980s. There were higher levels of reported sexual risk behaviour, younger 
age of sexual debut, and higher rates of curable STOs (gonorrhoea, chlamydia, 
trichmoniasis and active high-titre syphilis) in Mwanza than in the Ugandan trials except 
for Chlamydia in Ugandan men. The modelling work showed that the observed impact 
on HIV in the three trials was consistent with what would be expected based on the 
different risk behaviours and STO rates in the three trial populations. The popUlation 
differences were able to largely explain the observed differences in impact( I 08). 
In Masaka there was a reduction in HIV transmission already occurring in this 
setting(18) and during the trial we noted substantial secular changes towards safer 
sexual behaviour in the whole study population, unrelated to the main trial interventions, 
possibly due the nationwide prevention messages through the media and from other 
agencies. We reported from the same population that a substantial proportion (89%) of 
those who could change their behaviour had already done so(109). It is possible that 
even well designed and conducted IEe/STD interventions would have little chance of 
demonstrating a change in sexual behaviour in the presence of pre-existing background 
changes in a mature epidemic as in the Masaka trial population. 
In summary the Mwanza trial in Tanzania demonstrated the concept of syndromic STD 
management in the control of HlV transmission. The lack of impact on HIV incidence in 
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the Masaka trial was due to interventions not being applied to the right population at the 
right time. The Ugandan epidemic was mature, characterised by an existing reduction in 
risky sexual behaviour and lower rates of curable STDs at the time of the trial. In mature 
epidemics a larger proportion of new H IV infections would tend to occur in stable 
sexual partnerships in which STD rates are lower. When STD rates are lower the 
biological mechanisms through which STDs affect both the infectiousness of H IV 
(increase in HIV shedding) and susceptibility to HIV (increase in HIV susceptible 
inflammatory cells and disruption of the mucosa l barriers) are likely to play les a role in 
HIV transmission. 
Figure 3.2a Proportion (%) reporting two or more sex partners in the past year by age 
and sex 
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Figure 3.2b Prevalence (%) of high-titre serological syphilis (TPHA+/RPR ｾ＠ 1:8 
and sex at the start of the trials 
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Overall, we conclude that the concept of the interventions was right and the 
interventions were well-delivered but were "inert" because they were applied at the 
wrong stage of the epidemic and in a population where STD rates and risk behaviour 
had already decreased to a lower level. The design and conduct of the trial may also 
have affected the outcome as may the "sufficiency" of the interventions particularly the 
school-based programme of the IEC-component. 
3.4. Research on vaginal microbicides for HIV prevention 
Though HIV is predominantly transmitted through heterosexual intercourse in sub-
Saharan Africa, women are more vulnerable for several reasons including greater genital 
tissue exposure, socio-economic circumstances, and limited opportunity for negotiating 
safer sexual practices including condom usee 110-111). There is growing interest in 
developing and evaluating female-initiated HIV prevention methods that are not heavily 
dependent on partner negotiation. This includes the development of vaginal microbicidcs, 
a potential new female-controlled HIV prevention tool (1 12). There are various 
microbicide formulations, including vaginal gels, pessaries, film, and vaginal rings that 
release the active ingredient over time. Of the formulations that have been evaluated 
most are gels. 
In the last decade two generations of microbicides have been tested for safety and 
acceptability through various phases (I and lIa) and a few have gone through phase lIb 
and III safety and efficacy clinical trials. The first generation microbic ides were 
surfactants such as Nonoxynol-9 and Savvy that disrupt microbial cell membranes, 
thereby inactivating or killing the virus; and the vaginal defense enhancers that maintain 
or boost the naturally protective acidity of the vagina such as BufferGel(113). The 
second generation microbicides were entry inhibitors that block cellular receptors and 
prevent HlV from attaching to and infecting target cells. These include PR02000, 
Carraguard, and cellulose sulphate( 113). More recently, third generation products have 
been developed. These are ARV-based microbicides (tenofovir gel, UC-781 and 
dapivirine) that prevent HIV from replicating once inside a cell(l14). Unfortunately all 
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first and second generation products so far tested have not shown efficacy against HIV 
transmission. Encouragingly, the first Phase lIb of a third generation microbicide, 
tenofovir 1% gel, has shown efficacy (CAPRISA 004 trial)(37). 
3.4.1. Microbicide pllase II trial (safety and acceptability) 
We set out to establish suitable cohorts for evaluating potential microbicides in Uganda 
as described in chapter one through safety and acceptability (phase II), and safety and 
efficacy (phase III) clinical trials. After the failure of Nonoxynol-9( 115), a number of 
trials have been conducted to evaluate promising products including SAVVY(116), 
cellulose sulphate(117) and Carraguard(118). We evaluated PRO 2000 gel which is a 
microbicide polyanionic naphthalene sulphonate polymer that blocks infection with 
HIV, HSV-2, Neisseria gonorrheae, and Chlamydia trachomatis(119). A phase II trial 
was conducted among sexually active women aged 18-45 years in Kampala, Uganda to 
evaluate the safety and acceptability of two concentrations of PRO 2000 gel (0.5% and 
2%). After informed consent, women were randomized to 0.5% or 2% PRO 2000 gel or 
to a control arm (condoms only). Women in the gel arms were requested to use one 
applicator (approximately 2g of gel) intravaginally twice a day for 28 days. Follow-up 
visits were fortnightly up to 6 weeks from enrolment. The main findings were that both 
concentrations were found to be safe, acceptable and well tolerated( 120). In the light of 
these findings together with early safety studies elsewhere showing the safety and 
tolerability of PRO 2000(121-123), and promising in vitro and animal data, it was 
considered justifiable to evaluate the two concentrations in a large scale phase III 
efficacy trial. 
3.4.2. Phase III safety and efficacy trial 
A phase III randomized, double-blind trial to assess the efficacy and safety of 0.5% and 
2% PRO 2000 gels compared with a placebo gel for the prevention of vaginally acquired 
HIV infection was conducted in 4 sub-Saharan countries (South Africa, Zambia, 
Tanzania and Uganda) under the Microbicides Development Programme (MDP). The 
trial (MOP 301) was conducted between October 2005 and September 2009. Briefly, the 
trial enrolled sexually active HIV-negative women who were willing to give informed 
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consent, to have regular genital examinations and pregnancy tests, and to use the gel as 
per instructions. Out of 9385 women enrolled in the trial, 840 were enrolled in Uganda 
with a mean age of 32 years. The women were randomized to 0.5%, 2% and placebo in 
1:1:1 ratio and followed for 52 weeks (up to 104 weeks in Uganda). The trial also 
conducted social science research to evaluate gel acceptability and barriers to adherence. 
The primary outcome measures were HIV incidence, and grade 3 (severe) or 4 (life-
threatening) adverse events. The secondary outcome measures were HSV -2, Neisseria 
gonorrheae and Chlamyida trachomatis infections. In Uganda, the trial population was 
HIV-negative women living in an HIV discordant relationship, a study population in 
whom we had demonstrated good follow-up rates (II % loss to follow-up at one year) 
and an HIV incidence rate of approximately 12 per 100 person years of observation. 
The trial was monitored by an independent data safety monitoring committee (lOMe). 
In February, 2008 the committee recommended the discontinuation of the 2% gel arm as 
there was no more than a small chance of demonstrating benefit of that concentration. 
However women continued to be allocated to 0.5% gel or placebo. The retention at 52 
weeks of follow up was high - over 80% in all trial centres except in one centre with 
follow up of75%. Overall the gel was discontinued in 17% of women largely because of 
the withdrawal of 2% gel following the IOMC decision, and following pregnancy. The 
primary efficacy analysis included all HIV-negative women after enrolment and with 
follow-up data, and censored at 52 weeks of follow-up or pregnancy. A secondary 
efficacy analysis was done with the same criteria as the primary efficacy analysis, but 
without censoring for pregnancy and using all follow-up data. 
3.4.3. Summary of results 
The main trial results indicated that the gels were not effective in preventing lIIV 
transmission. HIV incidence at the end of the trial was 4.5 per 100 woman-years (95% 
CI 3.8-5.4) in the 0.5% gel arm and 4.3 (95% CI 3.6-5.2) in the placebo arm, with a 
hazard ratio of 1.05 (0.82-1.34). Similarly, there was no difference in incidence between 
trial arms when the efficacy analysis was done without censoring for pregnancy and 
including all follow-up data (table 3.3 At the time when the 2% gel arm was 
96 
discontinued HIV incidence was 4.7 (95% CI 3.8-5.8) in the 2% arm, 3.9 (95% CI 3.0-
4.9) in the 0.5% arm and 3.9 (95% CI 3.1-5.0) in the placebo gel arm. There was no 
difference in the incidence of primary safety endpoints between the trial arms(25). Early 
clinical studies and a phase lib trial (HPTN 035) had shown encouraging results that 
PRO 2000 gel would have an effect on HIV transmission in humans. The HPN035 trial 
that evaluated two gels (PRO 2000 gel and buffer gel) showed that PRO 2000 was 
associated with a 30% reduction in HIV transmission though this was not statistically 
significant, whereas buffer gel had no effect. However, in the larger MDP trial, 
PR02000 showed no significant effect. 
Table 3.3 Results ofMDP301 trial of PRO 2000: IIIV incidence 
Primary efficacy analysis· 
Participants 
Woman-years of follow-up 
Seroconversions 
Incidence 
Hazard ratio 
p value 
Secondary efficacy analysis± 
Participants 
Woman-years offollow-up 
Seroconversions 
Incidence 
Hazard ratio 
p value 
0.5% PR02000 
(0=3326) 
3156 
2873 
130 
4.5 (3.8-5.4) 
1.05 (0.82-1.34) 
0.71 
3156 
3133 
145 
4.6 (3.9-5.4) 
1.00( 0.79-1.26) 
0.99 
Placebo 
(n=3325) 
3112 
2836 
123 
4.3 (3.6-5.2) 
3112 
3099 
143 
4.6 (3.9-5.4) 
• Efficacy analysis censoring at 52 weeks of follow-up and pregnancy 
± Efficacy analysis without censoring for pregnancy and using all follow-up data 
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3.S. Why was there no reduction in HIV incidence in the 
MDP 301 trial? 
I have used the framework set out in section 3.3 to try to explain the lack of effect of 
PRO 2000 in the MOP 301 trial. That is (i) the concept is wrong; (ii) the concept is 
right but the actual intervention is "inert" or insufficient to demonstrate impact; and 
finally (iii) there were problems with the design or conduct of the trial. 
3.5.1 Was the concept of a microbicide gel to prevent HIV acqui.'iition wrong? 
There are various mechanisms of action through which microbic ides would prevent IIIV 
acquisition. The first and second generation microbicides were meant to act through 
disrupting the viral cell membranes (N-9, Saavy), enhancing vaginal defences (Buffer 
Gel) or blocking the HIV -target cell interactions (Carraguard, Cellulose Sulfate, 
PR02000). None of these products however, were able to demonstrate efficacy. Only 
recently has the concept of a microbicide in preventing HIV acquisition been proven in 
the CAPRISA 004 trial using tenofovir gel(37), the mechanism of which is through 
inhibiting HIV replication inside the target cells. Although further confirmatory trials 
are needed, this has provided evidence that the concept is right. 
3.5.2. Is the concept right but the actual intervention (PRO 200 gel) "inert"? 
The PRO 2000 gel tested in this trial was demonstrated to have anti-HIV activity in pre-
clinical studies. In these animal studies however HIV is introduced in the absence of 
physical sexual activity and hence there is no contact with seminal fluid. This is a 
different environment from that in clinical trials in humans, in which the product 
molecules are acting in the presence of female genital secretions, semen and physical 
coital activity. Some studies have indicated reduced antiviral activity of microbicides in 
the presence of seminal plasma(124-125). More recently, Keller and colleagues( 126) 
have demonstrated that there is significantly diminished antiviral activity 
(pharmacodynamics - PO) as well as lower concentrations (pharmacokinetics - PK) of 
PRO 2000 gel following coitus. The mechanisms of this are not fully understood but it 
is possible that seminal proteins may inhibit the binding of PRO 2000 molecules to the 
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target cells. Though Keller's study was small and based on a single-dose design with no 
placebo arm it offers a potential explanation for the lack of efficacy in the PRO 2000 gel 
trials and calls for conducting post-coital PD and PK studies in early clinical trials prior 
to designing large phase III trials. It thus appears that the particular product used in this 
trial (PRO 2000 gel) was "inert". 
3.5.3. Were there problems witlt tlte design or conduct of the trial? 
The trial was carefully designed to ensure adequate power taking into account loss to 
follow-up and censoring of women who became pregnant during the trial(25). Poor 
acceptability and adherence to product use could be one possible explanation, as these 
could affect potential effectiveness of the product. However, the gel was reported to be 
highly acceptable to both women and men, who often reported that it increased sexual 
pleasure(127). In a number of instances women were very unhappy to be withdrawn 
from gel at the end of their participation in the trial because it was felt that this would 
decrease their sexual pleasure. Equally important is the accurate measurement of 
adherence to gel use(128-129). There are a number of ways in which this could be 
measured such as self reporting through individual questionnaire interviews, in-depth 
interviews and coital diaries. There are also other more independent approaches, for 
example counts of used and returned gel applicators, and measuring biomarkers of the 
product in the body or on the returned applicators. The MDP trial had a social science 
component that collected relevant data to help in the interpretation of results. Adherence 
was measured using mixed methods that included clinic interviews, in-depth interviews, 
and coital diaries and counting the number of used applicators returned. The data were 
subsequently triangulated which is a method of combining results from different 
methods in an attempt to get a more accurate result(129). The triangulated data indicated 
that the adherence in this trial was high with no differences between the trial arms. The 
overall reported rate of gel use with and without condom use at the last sex act was 
approximately 90% at all visits. Hence non-adherence was unlikely to explain the lack 
of effect on HIV transmission(l28). 
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The product was designed to prevent vaginal acquisition of HIV and so if there was a 
significant frequency of anal sexual intercourse then the gel protection would have been 
less effective. Frequency of anal sex was assessed during the trial through individual 
interviews and focus group discussions. Only 2% of women reported anal sex in the 
trial, the majority of whom were from South Africa research centres. This low rate of 
anal sex is therefore unlikely to have affected the efficacy of PRO 2000 gel. There do 
not appear to have been major problems with the design of the trial. 
Overall, it seems that the concept of a microbicide is right and that the MDP 301 trial 
was well designed and conducted. However the particular product used for this 
intervention (PRO 2000 gel) was "inert". 
3.6. Conclusion 
Two large HIV intervention trials evaluating STD management in combination with 
behavioural change among Ugandan adults, and a vaginal microbicide gel among high 
risk HIV-negative women in four African countries, did not show any effect on HIV 
transmission. To explain these findings, a conceptual framework for discussing negative 
results from randomized controlled trials of HIV prevention has been used. That is (i) 
the concept is wrong; (ii) the concept is right but the actual intervention is "inert" or 
insufficient to demonstrate impact; (iii) there were problems with the design or conduct 
of the trial. 
The concepts of syndromic STD management and of a microbicide gel for the control of 
HIV transmission and acquisition were demonstrated by the Mwanza STD trial in 
Tanzania and the CAPRISA004 microbicide trial in South Africa, respectively. In both 
trials it appears that the explanation for the negative results is that the concept is right 
but the actual intervention was "inert" or insufficient to demonstrate impact. In the 
Masaka trial, the intervention was applied at the wrong stage of the epidemic in a 
population where STD rates and risk behaviour had already decreased. There was also 
evidence that there were deficiencies in the design and delivery of the school-based 
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component that did not fully comply with common characteristics of school 
programmes that have demonstrated positive impact in other settings. 
Despite these negative findings there are important lessons to be learnt from these and 
similar trials conducted elsewhere, which can infonn future HIV prevention research. 
The Masaka trial results together with data analysis from two other STD intervention 
trials in East Africa have indicated that the impact of STD control on H IV transmission 
depends on the stage of the HIV epidemic and the prevalence of STDs in a given 
population. The MDP study has demonstrated further that large microbicide trials can be 
conducted in Africa and that the acceptability of the product is high in both men and 
women. However there is a need to conduct more preliminary testing of microbicides, 
such as post-coital PD and PK studies, before large scale phase 3 trials are commenced. 
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Chapter 4. Important areas for future HIV prevention 
research 
Summary 
The HIV epidemic continues to pose many challenges, thirty years after AIDS was first 
reported. More people are living with HIV largely due to the availability of treatment 
but also due to continuing transmission. We have not been very successful in scaling up 
HIV preventive interventions especially for those at greatest risk. Over the last ten years, 
promising new prevention strategies have emerged but many of these have shown no 
effectiveness against HIV transmission and acquisition. There has, however been 
evidence from three recent trials in East and South Africa, which showed that male 
circumcision significantly reduces the risk of acquiring HlV. Building on advances in 
HIV treatment there is also recent evidence that antiretroviral drugs could provide 
prevention options through oral and topical pre-exposure prophylaxis and by using 
treatment to reduce the risk of HIV transmission. Though the discovery of an HlV 
vaccine remains elusive there are some new insights regarding where research needs to 
focus to advance this field. 
4.1. Introduction 
It is evident from data presented in the previous chapters that the HIV epidemic in 
Uganda continues to spread. Disappointingly, many of the interventions targeting 
Ugandan cohorts have had no effect on HIV transmission. Recently however, data from 
three trials of male medical circumcision in South Africa, Kenya and Uganda have 
shown approximately 60% protection among heterosexual males(33-35). A meta-
analysis of results of the three trials by Weiss and colleagues estimated incidence risk 
ratio of 0.42 (95% CI 0.31-0.57), which is 58% (95% CI 43-69%) protective effect of 
circumcision(l30). These data showed that male circumcision is probably the most 
effective biomedical HIV intervention to date. However, a comparable trial among 
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circumcised HIV-infected men showed no evidence that circumcision offers protection 
for their female partners(131). Despite this lack of protection for females, reduction of 
male HIV acquisition through circumcision does reduce women's exposure to HIV-
infected men and could therefore provide an overall benefit to women. 
There are various interventions that might be important for HIV prevention. Table 4.1 
shows a summary of prevention methods for HIV sexual transmission, which act at 
different stages of the proximate determinants framework. 
Table 4.1 HIV Prevention methods 
Category 
Structural 
Behavioural interventions 
Biological 
Intervention 
Increase access to HIV prevention/clinical 
services 
Stigma reduction 
Supporting policies and advocacy 
Micro-finance to poor vulnerable women 
including "conditional cash transfers" 
HIV counselling and testing 
Condoms (male and female) 
Sex health education 
Alcohol-related risk behaviour 
Treatment of STIs 
Male circumcision 
Microbicides (vaginal) 
ART for prevention 
Post exposure prophylaxis 
Oral pre-exposure prophylaxis 
Vaccines 
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This chapter focuses on future research on biological prevention methods that are 
relatively new and could potentially have a significant impact on HlV transmission. 
These include the role of antiretroviral drugs (ARV) for both oral and topical pre-
exposure prophylaxis (PrEP) as well as HlV treatment as prevention, lIlV vaccine 
research, and control of Herpes simplex virus type 2 (HSV -2). Future research priorities 
related to behavioural interventions are also briefly discussed. 
4.2. Role of antiretroviral therapy in IIIV prevention 
4.2.1. Pre-exposure Prophylaxis (PrEP) 
The use of ARV as pre-exposure prophylaxis in HIV prevention builds on the success of 
prophylaxis for other infectious diseases, for example malaria( 132-134), 
tuberculosis(135-136) and Pneumocystis pneumonia(137). More direct evidence of 
successful prophylaxis for HlV infection has come from the effectiveness of 
PMTCT(l38-140) and post-exposure prophylaxis (PEP}(I41·142). 
Over the last few years there has been considerable enthusiasm for the use of ARV in 
PrEP (oral and topical) for the prevention of HlV acquisition. This has been as a result 
of two factors. Firstly, new potent ARVs have become available to test the concept of 
PrEP in human clinical trials, mainly Tenofovir disoproxil fumarate (TDF) and a 
combination of EmtricitabinelTenofovir (FTCITDF) which have broad antiviral activity 
against both HIV viruses (HIV -I & -2). FTCITDF (Truvada) has favourable properties 
that also make it suitable for evaluation. These include its safety and tolerability profile, 
high drug levels in the genital tract and long intracellular half-lives, a high barrier to 
resistance, limited drug interactions with other drugs such as for tuberculosis and other 
antibiotics, easy to use on daily dosage (low pill burden) and relatively low cost due to 
the availability of generic formulations. 
Secondly, data from PrEP studies in animal models to prevent simian immunodeficiency 
virus (SIV) and HlV infection have shown encouraging efficacy(l43.144). 
Consequently, a number of PrEP clinical trials are ongoing in humans. A few have been 
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completed while others are in preparation (www.avac.org/trials).Briefly all these trials 
investigate the safety and efficacy of either TDF or FTCITDF in various populations. 
Results for some of these trials have started to emerge. 
For example in 2010, the iPrEx trial using FTCITDF among MSM in several countries 
(USA, South Africa, Thailand, Peru, Ecuador, and Brazil) demonstrated a 44% 
reduction in HIV incidence (95% CI, 15%- 63%; p= 0.005). The study provided the first 
evidence of protection against HIV acquisition using oral PrEP. The findings also 
indicated that detectable blood levels strongly correlated with the prophylactic 
effect(38). 
On the other hand, the Fern-PrEP trial that was evaluating once-daily oral Truvada 
versus placebo among high-risk heterosexual, HIV-negative women for HIV prevention 
was recently halted due to futility. A number of possible reasons have been suggested 
and include poor adherence and less penetration of oral Truvada in the genital tract. It 
has been suggested that rectal levels following oral dosing are higher than vaginal levels 
and this may explain the contrasting results of the iPrEx and Fern-PrEP trials(l45). It 
has also been shown that drugs delivered topically achieve higher penetration in the 
female genital tract than drugs delivered through oral dosing, which may explain the 
difference between the results of the CAPRISA 004 and Fern-PrEP trials(146). 
Encouraging as these finding are there are important questions that need to be addressed 
in future PrEP research. All the ongoing oral PrEP trials are evaluating daily dosing 
only. Are healthy HIV-uninfected recipients likely to adhere to a daily regimen for 
either long periods of time or for life? Successful PrEP will probably require sustained 
adherence. Unlike adherence to HIV treatment, little is known about the level, pattern 
and correlates of adherence to HIV biomedical prevention strategies such as PrEP. A 
better understanding of PrEP adherence behaviour will be essential to interpret clinical 
trial findings and maximize the effectiveness of PrEP. Are individuals likely to adhere 
more to an intermittent PrEP regimen? Understanding adherence to an intermittent 
regimen, its relationship to the timing of sexual activity and potential efficacy will be 
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important to evaluate. Such data will guide behavioural counselling regarding optimal 
use in roll out of PrEP interventions. 
4.2.2. H/V treatment as prevention 
The use of ARVs for the treatment of HIV has been one of the great successes in the 
epidemic even in countries with limited resources. Treatment initiatives have enabled 
greater access to treatment for many individuals resulting in improved survival and 
quality of Iife(147-149). As a means of identifying additional tools to reduce HIV 
transmission a new concept has emerged over recent years. That is to use ARV 
treatment for HIV prevention (Test and Treat). This involves universal HIV voluntary 
testing and treating HIV-infected individuals as early as possible with ARVs 
irrespective of CD4 cell count or other clinical guidelines. This could have benefits in 
reducing morbidity, mortality and transmission(150-151). If proved to be an effective 
prevention tool this could be particularly important in mature IIIV epidemics in many 
sub-Saharan countries where most HIV transmission occurs within stable IIlV 
discordant partnerships and where high risk behaviour plays a comparatively small role 
and marital partner poses the greatest risk( 152). 
This concept is based on evidence from a variety of sources. There are data from 
observational studies indicating a strong relationship between low viral load and a 
reduced risk of transmitting HIV to sexual partners in heterosexual populations(153). 
There is also evidence that reducing viral load by giving ART to the 1IlV-infected 
partner does indeed reduce transmission to a very low level( 154). 
Mathematical modelling has shown that a universal Test and Treat strategy may 
substantially reduce or even eliminate sexual transmission of HIV at a population 
level( 155). The model made various assumptions such as high compliance to 
antiretroviral therapy and the availability of second-line ART regimens. In addition, the 
model assumes that the period of acute or primary infection, when viral load is highest 
and the risk of 1I1V transmission considered greatest, lasts only about two months and 
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contributes to only 10% of HI V transmissions. In reality, acute or primary infection may 
make a greater contribution to HIV transmission. 
There is now an urgent need to establish whether this concept will work. There is 
additional evidence from the HPTN 052 trial that evaluated whether ARV treatment can 
prevent the sexual transmission of HIV among ART na"ive patients with a CD4+ cell 
count of 350-550 cells/mm3 in 1,750 serodiscordant couples in a number of countries 
(Botswana, Brazil, India, Kenya, Malawi, South Africa, Thailand and Zimbabwe). This 
was a two arm study in which arm 1 was randomised to ART upon enrolment plus IIIV 
primary care, while arm 2 was randomised to HIV primary care without initiation of 
ART until the participant had two consecutive CD4+ cell counts within or below the 
range of 200-250 cells/mm3, or developed an AIDS-defining illness. Early ART to HIV 
infected individuals showed a 96% reduction in the risk of HIV transmission to the HIV 
uninfected sexual partner (www.hptn.org). 
The ultimate goal is to evaluate the impact of Test and Treat on 1IIV transmission at a 
population level by conducting a CRT using HIV incidence as an outcome measure. 
Such a trial would be complex and expensive. However, prior to such a commitment 
there are several important research questions that need to be addressed that would 
inform the design and conduct of such a CRT: Is universal testing and provision of 
ARV to all who test HIV positive feasible at a population level? What are the best and 
most acceptable voluntary counselling and testing strategies in different populations? 
How can people with acute HIV infections be identified and started on treatment? What 
are the attitudes towards and acceptability of such a strategy in the general population, 
among health policy makers, funding agencies and other stakeholders? What is likely to 
be the cost-effectiveness of such an intervention? These questions will need to be 
addressed through feasibility and smaller pilot studies preferably in different countries 
in order to inform the final CRT design. 
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4.2.3. Third generation ARV-based microbicides 
The majority of new HIV infections continue to occur in women of child-bearing age 
through heterosexual transmission. Young women aged 15-24 years are as much as 
eight times more likely than young men to be HIV positive in sub-Saharan Africa(1). 
Among the many factors influencing female vulnerability to HIV transmission is the 
limited control they have over safer sexual practices such as using condoms. As 
discussed in chapter 3, there has been considerable interest in developing female-
controlled prevention methods, in particular the development and evaluation of vaginal 
microbicides. The field has now moved to third generation ARV-containing products. 
Of these the most advanced is Tenofovir (an NRTI), available in gel form. A phase lIb 
trial in South Africa (CAPRISA 004), reported a 39% reduction (95% CI 6%-60%, 
p=0.017) in HIV infection and a 51% reduction (95% CI 22%-70%, p=0.003) in HSV2 
infection among women using 1% tenofovir vaginal gel(37). The CAPRISA 004 trial 
design employed a coitally dependent regimen in which women were asked to apply gel 
up to 12 hours before sex and up to 12 hours after sex, and no more than twice in a 24 
hour period (BAT24). 
A second ongoing phase lib trial, MTN003 (VOICE) is evaluating a daily dose of 
Tenofovir vaginal gel in several African countries and will report results in 2013. While 
the CAPRISA trial results offer new hope in microbicide research, confirmatory trial 
results are required before licensing by regulatory bodies. The current thinking is that 
the ongoing VOICE trial would be sufficient, if it shows effectiveness. There are 
however other important research questions that need to be explored which could inform 
wider general population use of the gel. Would less frequent use of Tenofovir gel, such 
as a single-dose coitally dependant regimen, be as effective and safe as the complicated 
two dose regimen evaluated in the CAPRISA 004 trial? The rationale for this research 
question is that such dosing would be simpler and more convenient, and cheaper since a 
smaller amount of drug would be required. 
Other promising ARV-containing microbicide gel products are in development, 
including UC-781 and dapivirine (NNRTls) already in phase IIII clinical trials, and 
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Maraviroc (CCR5 blocker) in early preclinical trials. Depending on the safety profiles 
these are likely to go into larger phase lIb/III clinical trials. The current promising ARY-
containing microbicide products are largely being evaluated for prevention of 
heterosexual transmission but there is an equally urgent need to conduct rectal 
microbicide research. Receptive anal intercourse is a risk factor for lilY infection in 
both men and women. It is often difficult to obtain accurate data on the frequency of 
receptive anal sex in heterosexual populations although in some populations this may be 
significant( 1 56-1 57). An effective vaginal microbicide would not offer protection to 
those who practice anal sex. There are many differences between the rectum and the 
vagina that make the rectum more vulnerable to H IY. The vaginal wall is covered by 
many cell layers while the rectal walls are a single cell layer thick; the rectal wall 
contains many more CD4 receptors making them especially vulnerable to HlY; and the 
rectum has a more alkaline pH which is less protective than the acidic vaginal pIt 
Hence evaluation of rectal microbicides is urgently required for both men and women. 
Further microbicide research will be needed to explore delivery modes of the products 
other than a gel which is applied through an applicator and inserted in the vagina. These 
delivery methods include vaginal rings, film tablets and vaginal capsules. The vaginal 
ring impregnated with a microbicide is one approach that has already been advanced by 
the International Partnership for Microbicides (lPM) which is evaluating a dapivirine-
impregnated vaginal ring. Though current data suggest that daily gel use is acceptable 
with high adherence, the vaginal ring would be inserted for several weeks providing 
slow release of the active product, overcoming the need for daily or coitally dependent 
gel insertion. Further studies on the acceptability and safety of these delivery methods 
will be required. 
Research will also need to focus on evaluating microbicide products containing a 
combination of two or more ARYs either in gel or in ring form. As with HAART, use of 
microbicide combinations of products with different mechanisms of action could 
increase efficacy. For example the first combination microbicide (maraviroc and 
dapivirine) is already in a preclinical development phase. Whereas there are advantages 
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to such combination formulations, there are also potential disadvantages. There are 
likely to be difficulties in co-formulation, increased cost and increased potential for 
toxicity. All these will be important areas of research beyond the evaluation of effective 
single drug products. 
4.3. HIV vaccine research 
Much scientific effort has been put into HIV vaccine development as it is believed that 
this could be the best hope to end the epidemic. The overall aim is to develop a vaccine 
that could primarily prevent acquisition of infection and secondly control HIV 
progression in the event of infection. Despite the priority of vaccine development in 
HIV research, there has not been much success due to the challenges presented by the 
virus(l58). These include the genetic diversity of the virus even within a single infected 
individual; and the ability to infect the key cells of the immune system, particularly 
CD4+ T lymphocytes, in a relatively short time impairing the immune system in the first 
few weeks of infection. A successful vaccine would ideally need to meet these 
challenges. The few HIV vaccine trials conducted to date have generally shown no 
efficacy, including the STEP trial in which there was an increased risk of infection in a 
sub group of vaccine recipients( 159). The STEP trial aimed to assess the efficacy of a 
cell-mediated immunity vaccine against HIV infection and change in early plasma HIV 
levels. The most encouraging finding in the HIV vaccine field has been the recent Thai 
phase III trial (RVI44). This was a Phase III HIV vaccine trial that tested a "prime-
boost" combination of two vaccines: ALV AC® HIV vaccine (the prime) and 
AIDSV AX® B/E vaccine (the boost). The trial showed that the vaccine regimen was 
safe and of modest benefit with an efficacy of 31.2% (95% C[ 1.1-52.1). However, the 
vaccine regimen had no effect on viral load or CD4 cell count among volunteers who 
became HIV-infected during the study(36). 
Despite the limited progress made in mv vaccine research, there is evidence that 
provides some hope for future vaccine discovery. This is based on the observation that 
some HIV-infected individuals generate broadly cross-reacting neutralizing antibodies 
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(bNAbs). A number of these bNAbs have so far been identified (b 12, 2012, 2F5, 4E 10) 
and more recently P06 and PO 16 isolated from a c1ade-A infected African patient( 160). 
Though these bNAbs have been shown to provide sterilizing immunity in animal 
models(l61) there have been difficulties in using them in HIV vaccine development 
such as constructing an immunogen that elicits the desired antibody response in animal 
studies. Another piece of evidence comes from "elite controllers" or natural controllers, 
people who are HIV-infected for several years and maintain high CD4 and CD8 cell 
counts, and are treatment naYve as well as having undetectable viral load( 162). Further 
basic science research will need to focus on understanding better the role of broadly 
neutralizing antibodies and elite controllers in order to inform HIV vaccine design. 
4.4. Control of Herpes simp/ex virus typc-2 
Herpes simplex virus type-2 (HSV-2) infection is a common sexually transmitted 
infection and is the main cause of genital ulcer disease(l63-164). HSV-2 has been 
associated with an increased risk of HIV infection in a number of observational 
studies(l64-165). There are a number of ways in which HSV-2 may affect HIV 
infection: through increased transmission, acquisition and progression. However a 
number of recent well conducted clinical trials have found no effect of HSV-2 
suppressive therapy using acyclovir on the risk of HIV acquisition( 166) or 
transmission(167). Despite these findings, further research may still be necessary to 
evaluate HSV-2 treatment for HIV control. Important questions will include assessing 
whether HSV-2 suppressive therapy may have a greater impact among young HSV-2 
sero-converters, who on average will have been infected relatively recently and in whom 
HSV -2 clinical episodes are more frequent than in those who have had infection for 
several years. Though there is evidence that Acyclovir reduces mean plasma viral load 
of HIV, it is possible that a greater reduction is needed by using a higher dose and/or 
more potent anti-HSV -2 drugs. The finding that Tenofovir I % vaginal gel reduced 
HSV-2 acquisition in the CAPRISA 004 trial is an area that will require further 
exploration and confirmation as this could potentially increase the impact of the gel on 
IIIV transmission. 
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4.5. Future research priorities related to behaviour change 
interventions 
Several HIV intervention trials targeting behavioural change have been conducted, 
including several in sub Saharan Africa. A review of HlV behavioural intervention trials 
indicated that none had shown a significant impact on 1IlV acquisition among those that 
used HlV incidence as outcome measure. However some showed impact on other sexual 
and biological indicators such as reported sexual behaviour and reduction in HSV-2 
acquisition(168). Some of the possible reasons for these negative findings have included 
limitations of study design (sample size and duration of study), timing of interventions, 
and inadequacy of interventions. 
Despite these findings, there are possible future research priorities for behaviour change 
interventions. Firstly, interventions targeting mv positive individuals (positive 
prevention): most interventions have targeted HlV negative individuals and the effects 
of behavioural interventions targeted at mv positive individuals need further 
exploration. Secondly, interventions aimed at increasing condom promotion and use 
need to be considered given that this is still relatively low in many developing countries 
despite their potential impact. Other priority areas include behavioural interventions for 
special groups, such as married couples, especially those in mv discordant couple 
relationships; and individuals with concurrent partnerships. As most countries roll out 
ART programmes and other proven effective biomedical interventions, there is also a 
need to address issues that will help in understanding how best to avoid risk 
compensation in such programmes. Despite existing scientific evidence linking alcohol 
use with HIV sexual risk behaviour there has not been sufficient HIV prevention 
research in developing countries to address problem alcohol drinking( 169). 
Interventions aimed at reducing heavy alcohol use and reducing the frequency of 
consuming alcohol prior to sex in conjunction with community-based efforts to reduce 
HIV risk behaviour have the potential to reduce the spread of HIV and this calls for 
investigation. Finally in countries with mature epidemics it is important to ensure that 
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behavioural interventions are targeted at those individuals in whom the next new 
infections are likely to occur, based on knowledge of local epidemics - an approach 
referred to as "know your epidemic" and "know your response"( 170-172). 
4.6. Conclusion 
Though the most recent evidence of successful interventions and the focus for future 
HIV prevention research is on biomedical interventions there is a need to recognise that 
most of the biomedical interventions have strong behavioural components. The success 
of biomedical interventions that target both HIV transmission and acquisition will 
depend on understanding the impact of behavioural components such as acceptability, 
adherence and risk compensation. It is thus important that future HlV biomedical 
prevention research design should incorporate evaluation of behavioural aspects that 
will help in the interpretation of outcomes. 
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Chapter 5. Conclusion 
5.1. Introduction 
We are now three decades into the HIV/AIDS epidemic. HIV has had a devastating 
impact on the health, social and demographic characteristics of many countries 
especially in sub Saharan Africa(173-176). With substantial funding from a wide range 
of funding agencies, HIV research has been high on the agenda for many governments. 
This research has provided important information that has enabled us to understand the 
transmission dynamics, risk factors, magnitude and impact of the epidemic. Various 
interventions have been designed and evaluated in many settings, whose results have 
informed national and international policies on the management and control of the 
epidemic. A recent example is the policy on male circumcision, now in place in many 
countries following three successful circumcision trials. Despite these achievements, 
however, HIV remains one the greatest global health problems still being faced. 
In Uganda, strenuous efforts to understand and control HIV transmission were initiated 
in the early years of the epidemic. These efforts together with high-level political 
support led Uganda to be considered one of the world's success stories in controlling 
HIV/AIDS. This thesis is based on ten published papers arising from research on HIV 
epidemiology and on HIV interventions in rural South West Uganda, conducted between 
1989 and 2008. I have utilised data arising from my professional experience and the key 
role I played in establishing and following up unique cohorts for conducting mv 
epidemiological and intervention studies. I have examined three research questions that 
have implications for the control of HIV transmission in African populations. 
Firstly, what are the trends in HIV incidence and prevalence in Uganda? Secondly what 
are the key determinants of these trends? And finally what are the new strategies that 
could prevent HIV transmission in this population? 
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In chapter 1, I described the development of the MRC/uVRI research programme, the 
characteristics of the populations studied in the different studies, summarised the results 
from the ten published papers, and used a proximate-determinants framework to 
describe the key determinants of HIV incidence and prevalence that have been 
examined. In chapter 2, I critically examined trends in HIV incidence and prevalence 
during the study period and used the framework to explore the effects of underlying and 
proximate determinants on the trends observed during the study period. The limitations 
of the analysis, methods used are also discussed in this chapter. Chapter 3 described and 
critically assessed interventions to prevent HIV transmission in the study cohorts, and 
examined why some interventions showed no impact on transmission. Chapter 4 focused 
on future research on biological prevention methods that are relatively new and could 
potentially have a significant impact on HIV transmission. Future research priorities 
related to behavioural interventions are also discussed. In this final chapter I draw some 
conclusions arising from the work presented in the first four chapters and attempt to 
answer the three main questions outlined above. I begin with a note about the study 
populations on which my research was based. 
5.2. Study populations 
The cohorts in which this research was conducted were relatively stable, rural and semi-
urban populations. We have been able to follow these cohorts and obtain longitudinal 
epidemiological data over a 20-year period through annual demographic and serological 
surveys with high participation rates. Of the adults enumerated at each survey round, 
75.8% had a confirmed HIV test result in that round(l4). These are some of the longest 
continuing HlV cohorts in Africa, established early in the epidemic enabling us to 
monitor trends in HIV incidence and prevalence in a systematic manner up to the 
present day. 
We used similar methods of data collection, statistical analysis and laboratory testing 
throughout the study period. The age and sex distribution also remained the same 
throughout the period. Overall the total size of the population has not changed as in-
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migration (including births) has been similar to out-migration (including deaths); 10.7% 
and 10.3% respectively. Thus the data from which the HIV trends and risk factors have 
been derived are robust and could be generalisable to other, similar populations 
elsewhere in Uganda. 
To prepare for future HIV prevention research, we carefully considered the need to 
establish population cohorts that would be most suitable for this work. It was important 
to identify cohorts with high HIV incidence as this is a primary outcome measure for 
many HIV intervention trials. One such cohort has been described, composed of HIV 
negative adults living in serodiscordant stable relationships. This cohort was used 
successfully to recruit participants for a large phase III vaginal microbicide. 
5.3. Trends in HIV prevalence and incidence in Uganda 
I examined HIV prevalence and incidence trends in Uganda. Overall there was a 
significant decline in HlV prevalence in both sexes, especially in those aged 20-24 years 
between 1990 and 2000. Thereafter there was a clear reversal in trends, with HlV 
prevalence rising steadily until 2008. However, the trends in those aged 35 years and 
above have been the most discouraging - rising throughout the study period. It was not 
surprising that HIV prevalence was higher among females than in males, a finding that 
has been documented in many epidemiological studies in SSA(32, 69). 
Although there are limitations in the analysis of time trends based on our cohort data, 
the findings from this thesis were broadly consistent with data from other sources in 
Uganda. Of particular interest are the data from the neighbouring Rakai Programme 
cohort and from the national surveillance system. Both indicated a similar decline in 
HIV prevalence in the 1990s but with less clear evidence of a subsequent increase in 
prevalence. 
HIV incidence trends were more difficult to interpret because of the relatively small 
number of seroconversions each year. Earlier analysis up to 1999 indicated a decline in 
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HIV incidence in the 1990s for both men and women. Further analysis up to 2008 
showed a significant decline in all ages between 1990 and 2000, and a non significant 
increase between 2001 and 2008. We did not observe any sex difference in incidence 
rates between men and women throughout the period. The observation that prevalence 
and incidence were already declining from the late 1980s and early 1990s when the 
MRC cohort was established suggests that the decline could have started a few years 
earlier. This has been supported by modelling of HI V incidence(S7). 
5.4. Key determinants of the trends 
The key determinants that contributed to the decrease in H IV prevalence during the 
1990s were a net outflow of HIV positive migrants, more deaths of HIV positive 
individuals and reductions in risky sexual behaviour, as well as the natural course of the 
epidemic. A number of factors could have led to these trends in sexual behaviour, 
including nationwide health campaigns, improved STD management and high-level 
political support. The increase in HIV prevalence from 2000 is more difficult to explain 
although improved survival due to ART, an increase in high risk sexual risk behaviour 
and a shift in government efforts away from HIV prevention could all have contributed. 
Trends in HIV incidence rates were less clear than prevalence trends. The decline in 
incidence seen from the early 1990s could be an indication that the decline could have 
started earlier, possibly in the late 1980s. 
5.5. New HIV prevention strategies 
Health education targeting safer sexual behaviour has been the cornerstone of HIV 
prevention, but current trends in HIV incidence and prevalence clearly indicate that this 
alone is not sufficient to control the epidemic. In an attempt to fill this gap several 
interventions have been evaluated. I have described two large intervention trials that 
evaluated the impact on HIV acquisition of improved STD management in combination 
with behavioural change, and a vaginal microbicide gel. Neither trial showed efficacy. 
Although the concepts underpinning these trials were correct, the interventions were 
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insufficient to demonstrate impact. Several other HIV intervention trials in other settings 
have also not shown efficacy against HIV transmission(98}. As a consequence, there has 
been a call for new prevention strategies which were discussed in chapter 4. These 
include oral and topical pre-exposure prophylaxis using antiretroviral drugs, lIlV 
treatment as prevention (i.e. early treatment of people with HIV to reduce their 
infectiousness) and HIV vaccines. There have been recent efforts to roll-out medical 
male circumcision (MMC) in many African countries including Uganda. It is too early 
to determine whether MMC together with existing behavioural approaches will be 
sufficient to bring the epidemic under control. The success of these biomedical 
interventions will to a large extent depend on behavioural factors such as acceptability, 
adherence and risk compensation. I recognise that there are other research priorities 
related to behavioural change interventions unrelated to biomedical interventions which 
will also require evaluation. 
5.6. Further research 
The concept of phase-specific dynamics of HIV epidemiology(l77) suggests that the 
infection retreats into higher risk subgroups of the population as the epidemic matures, 
as is the case in Uganda. The networks in such subgroups strongly influence the risk of 
transmission and subsequently have important implications for interventions. There is 
evidence that HIV prevalence in Uganda and in other countries may be elevated in 
certain high risk population sub groups that deserve special attention and further 
research. These include individuals living in fishing communities and women engaged 
in sex work. It is estimated that HIV prevalence in African fishing communities is much 
higher (probably 3-4 times) than the national average(l78-179). These high infection 
rates have been attributed to a number factors such as limited access to prevention and 
treatment, high alcohol consumption and behavioural characteristics including multiple 
and concurrent sexual partners as well as sexual networks reaching both within and 
outside the community. There have been several studies among sex workers in a number 
of African countries which have documented high rates of STOs and lIIV infection( 180-
181}. Some of the studies have also evaluated interventions targeted to these 
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groups(182-183). Intensive HIV prevention using proven effective interventions in these 
high risk populations is an area of high priority for Uganda. 
5.7. Conclusion 
The research I have conducted with my colleagues in Uganda has allowed us to monitor 
and understand trends in HIV incidence and prevalence. The research has also helped 
us understand which strategies for HIV prevention will work in this population. 
Hopefully, the cohorts we established in Uganda in the 1980s wiII continue to provide 
new opportunities for monitoring and preventing the transmission of HIV in this 
population in the future. 
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